Bicyclic compounds as dual atx/ca inhibitors

ABSTRACT

The invention provides novel compounds having the general formula (I) 
     
       
         
         
             
             
         
       
     
     wherein R 1 , R 2 , R 9 , Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.

The present invention relates to organic compounds useful for therapy orprophylaxis in a mammal, and in particular to dual autotaxin(ATX)/carbonic anhydrase inhibitors which are inhibitors oflysophosphatidic acid (LPA) production and thus modulators of LPA levelsand associated signaling, for the treatment or prophylaxis ofinflammatory conditions, conditions of the nervous system, vascular andcardiovascular conditions, cancer, and ocular conditions.

The present invention provides novel compounds of formula (I)

wherein

-   -   R¹ is substituted phenyl, substituted phenyl-C₁₋₆-alkyl,        substituted phenoxy-C₁₋₆-alkyl, substituted phenyl-C₂₋₆-alkenyl,        substituted phenyl-C₂₋₆-alkynyl, substituted pyridinyl,        substituted pyridinyl-C₁₋₆-alkyl, substituted        pyridinyl-C₂₋₆-alkenyl, substituted pyridinyl-C₂₋₆-alkynyl,        substituted thiophenyl, substituted thiophenyl-C₁₋₆-alkyl,        substituted thiophenyl-C₂₋₆-alkenyl or substituted        thiophenyl-C₂₋₆-alkynyl, wherein substituted phenyl, substituted        phenyl-C₁₋₆-alkyl, substituted phenoxy-C₁₋₆-alkyl, substituted        phenyl-C₂₋₆-alkenyl, substituted phenyl-C₂₋₆-alkynyl,        substituted pyridinyl, substituted pyridinyl-C₁₋₆-alkyl,        substituted pyridinyl-C₂₋₆-alkenyl, substituted        pyridinyl-C₂₋₆-alkynyl, substituted thiophenyl, substituted        thiophenyl-C₁₋₆-alkyl, substituted thiophenyl-C₂₋₆-alkenyl and        substituted thiophenyl-C₂₋₆-alkynyl are substituted by R³, R⁴        and R⁵;    -   Y is —OC(O)— or —C(O)—;    -   W is —C(O)—, —S(O)₂— or —CR⁶R⁷—;    -   R² is substituted phenyl, substituted pyridinyl or substituted        thiophenyl, wherein substituted phenyl, substituted pyridinyl        and substituted thiophenyl are substituted by R⁶, R⁷ and R⁸;    -   R³ is halogen, hydroxy, cyano, C₁₋₆-alkyl, C₁₋₆-alkoxy,        C₁₋₆-alkoxy-C₁₋₆-alkyl, halo-C₁₋₆-alkoxy, halo-C₁₋₆-alkyl,        hydroxy-C₁₋₆-alkyl, C₃₋₈-cycloalkyl, C₃₋₈-cycloalkyl-C₁₋₆-alkyl,        C₃₋₈-cycloalkyl-C₁₋₆-alkoxy, C₃₋₈-cycloalkoxy,        C₃₋₈-cycloalkoxy-C₁₋₆-alkyl, C₁₋₆-alkylamino,        C₁₋₆-alkylcarbonylamino, C₃₋₈-cycloalkylcarbonylamino,        C₁₋₆-alkyltetrazolyl, C₁₋₆-alkyltetrazolyl-C₁₋₆-alkyl or        heterocycloalkyl-C₁₋₆-alkoxy;    -   R⁴ and R⁵ are independently selected from H, halogen, hydroxy,        cyano, C₁₋₆-alkyl, C₁₋₆-alkoxy, C₁₋₆-alkoxy-C₁₋₆-alkyl,        halo-C₁₋₆-alkoxy, halo-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl,        C₃₋₈-cycloalkyl, C₃₋₈-cycloalkyl-C₁₋₆-alkyl,        C₃₋₈-cycloalkyl-C₁₋₆-alkoxy, C₃₋₈-cycloalkoxy,        C₃₋₈-cycloalkoxy-C₁₋₆-alkyl, C₁₋₆-alkylcarbonylamino,        C₃₋₈-cycloalkylcarbonylamino, C₁₋₆-alkyltetrazolyl,        C₁₋₆-alkyltetrazolyl-C₁₋₆-alkyl or heterocycloalkyl-C₁₋₆-alkoxy;    -   R⁶ is aminosulfonyl;    -   R⁷ and R⁸ are independently selected from H, halogen, hydroxy,        cyano, C₁₋₆-alkyl, C₁₋₆-alkoxy, C₁₋₆-alkoxy-C₁₋₆-alkyl,        halo-C₁₋₆-alkoxy, halo-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl,        C₃₋₈-cycloalkyl, C₃₋₈-cycloalkyl-C₁₋₆-alkyl,        C₃₋₈-cycloalkyl-C₁₋₆-alkoxy, C₃₋₈-cycloalkoxy and        C₃₋₈-cycloalkoxy-C₁₋₆-alkyl;    -   R⁹ is C₁₋₆-alkyl, C₁₋₆-alkoxy or halogen;    -   m, n, p and q are independently selected from 1 or 2;    -   or pharmaceutically acceptable salts.

Autotaxin (ATX) is a secreted enzyme also called ectonucleotidepyrophosphatase/phosphodiesterase 2 or lysophospholipase D that isimportant for converting lysophosphatidyl choline (LPC) to the bioactivesignaling molecule lysophosphatidic acid (LPA). It has been shown thatplasma LPA levels are well correlated with ATX activity and hence ATX isbelieved to be an important source of extracellular LPA. Earlyexperiments with a prototype ATX inhibitor have shown that such acompound is able to inhibit the LPA synthesizing activity in mouseplasma. Work conducted in the 1970s and early 1980s has demonstratedthat LPA can elicit a wide range of cellular responses; including smoothmuscle cell contraction, platelet activation, cell proliferation,chemotaxis and others. LPA mediates its effects via signaling to severalG protein coupled receptors (GPCRs); the first members were originallydenoted Edg (endothelial cell differentiation gene) receptors orventricular zone gene-1(vzg-1) but are now called LPA receptors. Theprototypic group now consists of LPA1/Edg-2/VZG-1, LPA2/Edg-4, andLPA3/Edg-7. Recently, three additional LPA receptors LPA4/p2y9/GPR23,LPA5/GPR92 and LPA6/p2Y5 have been described that are more closelyrelated to nucleotide-selective purinergic receptors than to theprototypic LPA1-3 receptors. The ATX-LPA signaling axis is involved in alarge range of physiological and pathophysiological functions,including, for example, nervous system function, vascular development,cardiovascular physiology, reproduction, immune system function, chronicinflammation, tumor metastasis and progression, organ fibrosis as wellas obesity and/or other metabolic diseases such as diabetes mellitus.Therefore, increased activity of ATX and/or increased levels of LPA,altered LPA receptor expression and altered responses to LPA maycontribute to the initiation, progression and/or outcome of a number ofdifferent pathophysiological conditions related to the ATX/LPA axis.

Carbonic anhydrases (CA) are a family of zinc-dependent enzymes, whichcatalyze the equilibration between carbon dioxide and water andhydrogencarbonate and a proton. The CA reaction is involved in manyphysiological and pathological processes. Carbonic anhydrase inhibitionis useful for the treatment of ocular conditions, conditions of reducedblood flow, cancer, edema and inflammatory conditions includingbacterial infections.

Dual acting ATX/CA inhibitors are expected to lower intraocular pressureby facilitating two independent pathways, such as inhibition of aqueoushumor (AH) production through CA inhibition at the ciliary body andfacilitation of AH outflow by ATX inhibition within the AH drainagesystem. In conditions of vascular leakage in the eye such as diabeticretinopathy, age related macular disease, or retinal vein occlusion, CAlevels have been shown or are expected to increase in the eye andfacilitate an increase in pH. This is expected to activate manyhydrolytic enzymes that can contribute to disease progression includingATX suggesting additional ATX inhibition by shifting the pH optimum.

In accordance with the invention, the compounds of formula (I) or theirpharmaceutically acceptable salts and esters can be used for thetreatment or prophylaxis of diseases, disorders or conditions that areassociated with the activity of autotaxin and/or the biological activityof lysophosphatidic acid (LPA).

The compounds of formula (I) or their pharmaceutically acceptable saltsand esters herein inhibit autotaxin activity and carbonic anhydraseactivity therefore inhibit LPA production and modulate LPA levels andassociated signaling. Dual ATX/CA-II inhibitors described herein areuseful as agents for the treatment or prevention of diseases orconditions in which ATX activity and/or LPA signaling participates, isinvolved in the etiology or pathology of the disease, or is otherwiseassociated with at least one symptom of the disease. The ATX-LPA axishas been implicated for example in angiogenesis, chronic inflammation,autoimmune diseases, fibrotic diseases, cancer and tumor metastasis andprogression, ocular conditions, metabolic conditions such as obesityand/or diabetes mellitus, conditions such as cholestatic or other formsof chronic pruritus as well as acute and chronic organ transplantrejection.

Objects of the present invention are the compounds of formula (I) andtheir aforementioned salts and esters and their use as therapeuticallyactive substances, a process for the manufacture of the said compounds,intermediates, pharmaceutical compositions, medicaments containing thesaid compounds, their pharmaceutically acceptable salts or esters, theuse of the said compounds, salts or esters for the treatment orprophylaxis of disorders or conditions that are associated with theactivity of ATX and/or the biological activity of lysophosphatidic acid(LPA), particularly in the treatment or prophylaxis of inflammatoryconditions, conditions of the nervous system, conditions of therespiratory system, vascular and cardiovascular conditions, fibroticdiseases, cancer, ocular conditions, metabolic conditions, cholestaticand other forms of chronic pruritus and acute and- chronic organtransplant rejection, and the use of the said compounds, salts or estersfor the production of medicaments for the treatment or prophylaxis ofinflammatory conditions, conditions of the nervous system, conditions ofthe respiratory system, vascular and cardiovascular conditions, fibroticdiseases, cancer, ocular conditions, metabolic conditions, cholestaticand other forms of chronic pruritus and acute and chronic organtransplant rejection. More particularly, the compounds of formula (I)and their aforementioned salts and esters and their use astherapeutically active substances, a process for the manufacture of thesaid compounds, intermediates, pharmaceutical compositions, medicamentscontaining the said compounds, their pharmaceutically acceptable saltsor esters, the use of the said compounds, salts or esters for thetreatment or prophylaxis of ocular conditions, furthermore particularlyglaucoma.

The term “C₁₋₆-alkoxy” denotes a group of the formula —O—R′, wherein R′is an C₁₋₆-alkyl group. Examples of C₁₋₆-alkoxy group include methoxy,ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy and tert-butoxy.Particular example is methoxy.

The term “C₂₋₆-alkenyl” denotes a monovalent linear or branchedhydrocarbon group of 2 to 6 carbon atoms with at least one double bond.Particular example is ethylenyl.

The term “C₁₋₆-alkoxy-C₁₋₆-alkyl” denotes a C₁₋₆-alkyl group wherein atleast one of the hydrogen atoms of the C₁₋₆-alkyl group is replaced by aC₁₋₆-alkoxy group. Particular examples are methoxymethyl, methoxyethyl,ethoxymethyl, ethoxyethyl, iso-propoxymethyl and iso- propoxyethyl.

The term “C₁₋₆-alkyl” denotes a monovalent linear or branched saturatedhydrocarbon group of 1 to 6 carbon atoms. Examples of C₁₋₆-alkyl includemethyl, ethyl, propyl, isopropyl, n-butyl, iso-butyl, sec-butyl,tert-butyl and pentyl. Particular alkyl groups include methyl, ethyl,isopropyl, n-butyl and sec-butyl.

The term “C₁₋₆-alkylamino” a group of the formula —NH— R′, wherein R′ isan C₁₋₆-alkyl group. Particular C₁₋₆-alkylamino is a group of theformula —NH— R′, wherein R′ is ter-butyl.

The term “C₁₋₆-alkylcarbonylamino” denotes a group of the formula—NH—C(O)—R′, wherein R′ is an C₁₋₆-alkyl group. ParticularC₁₋₆-alkylcarbonylamino is a group of the formula —NH—C(O)—R′, whereinR′ is ter-butyl.

The term “C₁₋₆-alkyltetrazolyl” denotes tetrazolyl group substitutedwith one C₁₋₆-alkyl group. Particular C₁₋₆-alkyltetrazolyl ismethyltetrazolyl.

The term “C₁₋₆-alkyltetrazolyl-C₁₋₆-alkyl” denotes C₁₋₆-alkyl groupwherein one of the hydrogen atoms of the C₁₋₆-alkyl group is replaced bya C₁₋₆-alkyltetrazolyl group. Particular example ismethyltetrazolylmethyl.

The term “C₂₋₆-alkynyl” denotes a monovalent linear or branchedhydrocarbon group of 2 to 6 carbon atoms with at least one triple bond.

The term “amino” denotes the —NH₂ group.

The term “aminosulfonyl” denotes —S(O)₂—NH₂ group.

The term “cyano” denotes a —C≡N group.

The term “C₃₋₈-cycloalkoxy” denotes a group of the formula —O—R′,wherein R′ is a C₃₋₈-cycloalkyl.

The term “C₃₋₈-cycloalkoxy-C₁₋₆-alkyl” denotes a C₁₋₆-alkyl groupwherein at least one of the hydrogen atoms of the alkyl group isreplaced by a C₃₋₈-cycloalkoxy group.

The term “C₃₋₈-cycloalkyl” denotes a monovalent saturated monocyclic orbicyclic hydrocarbon group of 3 to 8 ring carbon atoms. Bicyclic means aring system consisting of two saturated carbocycles having two carbonatoms in common. Examples for monocyclic cycloalkyl are cyclopropyl,cyclobutanyl, cyclopentyl, cyclohexyl or cycloheptyl. Examples forbicyclic C₃₋₈-cycloalkyl are bicyclo[2.2.1]heptanyl orbicyclo[2.2.2]octanyl. Particular C₃₋₈-cycloalkyl group is cyclopropyl.

The term “C₃₋₈-cycloalkyl-C₁₋₆-alkoxy” denotes a C₁₋₆-alkoxy groupwherein at least one of the hydrogen atoms of the alkyl group isreplaced by a C₃₋₈-cycloalkyl group.

The term “C₃₋₈-cycloalkyl-C₁₋₆-alkyl” denotes a C₁₋₆-alkyl group whereinat least one of the hydrogen atoms of the alkyl group is replaced by aC₃₋₈-cycloalkyl group.

The term “C₃₋₈-cycloalkylcarbonylamino” denotes a group of the formula—NH—C(O)—R′, wherein R′ is a C₃₋₈-cycloalkyl group.

The term “halo-C₁₋₆-alkoxy” denotes a C₁₋₆-alkoxy group wherein at leastone of the hydrogen atoms of the alkoxy group has been replaced by thesame or different halogen atoms. Particular examples aretrifluoromethoxy.

The term “halogen” and “halo” are used interchangeably herein and denotefluoro, chloro, bromo or iodo. Particular halogens are chloro andfluoro.

The term “halo-C₁₋₆-alkyl” denotes a C₁₋₆-alkyl group wherein at leastone of the hydrogen atoms of the C₁₋₆-alkyl group has been replaced bythe same or different halogen atoms. Particular examples aretrifluoromethyl.

The term “heterocycloalkyl” denotes a monovalent saturated or partlyunsaturated mono- or bicyclic ring system of 4 to 9 ring atoms,comprising 1, 2, or 3 ring heteroatoms selected from N, O and S, theremaining ring atoms being carbon. Bicyclic means consisting of twocycles having two ring atoms in common, i.e. the bridge separating thetwo rings is either a single bond or a chain of one or two ring atoms.Examples for monocyclic saturated heterocycloalkyl are4,5-dihydro-oxazolyl, oxetanyl, azetidinyl, pyrrolidinyl,2-oxo-pyrrolidin-3-yl, tetrahydrofuranyl, tetrahydro-thienyl,pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl,thiazolidinyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl,piperazinyl, morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholin-4-yl,azepanyl, diazepanyl, homopiperazinyl, or oxazepanyl. Examples forbicyclic saturated heterocycloalkyl are 8-aza-bicyclo[3.2.1]octyl,quinuclidinyl, 8-oxa-3-aza-bicyclo[3.2.1]octyl,9-aza-bicyclo[3.3.1]nonyl, 3-oxa-9-aza-bicyclo[3.3.1]nonyl, or3-thia-9-aza-bicyclo[3.3.1]nonyl. Examples for partly unsaturatedheterocycloalkyl are dihydrofuryl, imidazolinyl, dihydro-oxazolyl,tetrahydro-pyridinyl, or dihydropyranyl. Particular example ofheterocycloalkyl group is tetrahydropyranyl.

The term “heterocycloalkyl-C₁₋₆-alkoxy” denotes a C₁₋₆-alkoxy groupwherein at least one of the hydrogen atoms of the alkyl group isreplaced by a heterocycloalkyl group. Particular example ofheterocycloalkyl-C₁₋₆-alkoxy is tetrahydropyranyl-C₁₋₆-alkoxy, moreparticularly tetrahydropyranylmethoxy.

The term “hydroxy” denotes a —OH group.

The term “hydroxy-C₁₋₆-alkyl” denotes a C₁₋₆-alkyl group wherein one ofthe hydrogen atoms of the alkyl group is replaced by a hydroxy group.Particular examples are hydroxymethyl and hydroxyethyl.

The term “phenoxy” denotes a group of the formula —O—R′, wherein R′ is aphenyl group.

The term “phenoxy-C₁₋₆-alkyl” denotes a C₁₋₆-alkyl group wherein one ofthe hydrogen atoms of the alkyl group is replaced by a phenoxy group.

The term “phenyl-C₂₋₆-alkenyl” denotes a C₂₋₆-alkenyl group wherein oneof the hydrogen atoms of the alkyl group is replaced by a phenyl group.Particular example of phenyl-C₂₋₆-alkenyl is phenylethenyl.

The term “phenyl-C₁₋₆-alkyl” denotes a C₁₋₆-alkyl group wherein one ofthe hydrogen atoms of the alkyl group is replaced by a phenyl group.Particular examples of phenyl-C₁₋₆-alkyl are phenylmethyl andphenylethyl.

The term “phenyl-C₂₋₆-alkynyl” denotes a C₂₋₆-alkynyl group wherein oneof the hydrogen atoms of the alkyl group is replaced by a phenyl group.

The term “pyridinyl-C₂₋₆-alkenyl” denotes a C₂₋₆-alkenyl group whereinone of the hydrogen atoms of the alkyl group is replaced by a pyridinylgroup.

The term “pyridinyl-C₁₋₆-alkyl” denotes a C₁₋₆-alkyl group wherein oneof the hydrogen atoms of the alkyl group is replaced by a pyridinylgroup. Particular example of pyridinyl-C₁₋₆-alkyl is pyridinylmethyl,more particularly 2-pyridinylmethyl.

The term “pyridinyl-C₂₋₆-alkynyl” denotes a C₂₋₆-alkynyl group whereinone of the hydrogen atoms of the alkyl group is replaced by a pyridinylgroup.

The term “thiophenyl-C₂₋₆-alkenyl” denotes a C₂₋₆-alkenyl group whereinone of the hydrogen atoms of the alkyl group is replaced by a thiophenylgroup.

The term “thiophenyl-C₁₋₆-alkyl” denotes a C₁₋₆-alkyl group wherein oneof the hydrogen atoms of the alkyl group is replaced by a thiophenylgroup.

The term “thiophenyl-C₂₋₆-alkynyl” denotes a C₂₋₆-alkynyl group whereinone of the hydrogen atoms of the alkyl group is replaced by a thiophenylgroup.

The term “pharmaceutically acceptable salts” refers to those salts whichretain the biological effectiveness and properties of the free bases orfree acids, which are not biologically or otherwise undesirable. Thesalts are formed with inorganic acids such as hydrochloric acid,hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and thelike, in particular hydrochloric acid, and organic acids such as aceticacid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleicacid, malonic acid, succinic acid, fumaric acid, tartaric acid, citricacid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid,ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid,N-acetylcystein and the like. In addition, these salts may be preparedby addition of an inorganic base or an organic base to the free acid.Salts derived from an inorganic base include, but are not limited to,the sodium, potassium, lithium, ammonium, calcium, magnesium salts andthe like. Salts derived from organic bases include, but are not limitedto salts of primary, secondary, and tertiary amines, substituted aminesincluding naturally occurring substituted amines, cyclic amines andbasic ion exchange resins, such as isopropylamine, trimethylamine,diethylamine, triethylamine, tripropylamine, ethanolamine, lysine,arginine, N-ethylpiperidine, piperidine, polyimine resins and the like.Particular pharmaceutically acceptable salts of compounds of formula (I)are the hydrochloride salts, methanesulfonic acid salts and citric acidsalts.

“Pharmaceutically acceptable esters” means that compounds of generalformula (I) may be derivatised at functional groups to providederivatives which are capable of conversion back to the parent compoundsin vivo. Examples of such compounds include physiologically acceptableand metabolically labile ester derivatives, such as methoxymethylesters, methylthiomethyl esters and pivaloyloxymethyl esters.Additionally, any physiologically acceptable equivalents of thecompounds of general formula (I), similar to the metabolically labileesters, which are capable of producing the parent compounds of generalformula (I) in vivo, are within the scope of this invention.

The term “protecting group” (PG) denotes a group which selectivelyblocks a reactive site in a multifunctional compound such that achemical reaction can be carried out selectively at another unprotectedreactive site in the meaning conventionally associated with it insynthetic chemistry. Protecting groups can be removed at the appropriatepoint. Exemplary protecting groups are amino-protecting groups,carboxy-protecting groups or hydroxy-protecting groups. Particularprotecting groups are the tert-butoxycarbonyl (Boc), benzyloxycarbonyl(Cbz), fluorenylmethoxycarbonyl (Fmoc) and benzyl (Bn) groups. Furtherparticular protecting groups are the tert-butoxycarbonyl (Boc) and thefluorenylmethoxycarbonyl (Fmoc) groups. More particular protecting groupis the tert-butoxycarbonyl (Boc) group.

The abbreviation uM means microMolar and is equivalent to the symbol μM.

The abbreviation uL means microliter and is equivalent to the symbol μL.

The abbreviation ug means microgram and is equivalent to the symbol μg.

The compounds of formula (I) can contain several asymmetric centers andcan be present in the form of optically pure enantiomers, mixtures ofenantiomers such as, for example, racemates, optically purediastereoisomers, mixtures of diastereoisomers, diastereoisomericracemates or mixtures of diastereoisomeric racemates.

According to the Cahn-Ingold-Prelog Convention the asymmetric carbonatom can be of the “R” or “S” configuration.

Also an embodiment of the present invention are compounds according toformula (I) as described herein and pharmaceutically acceptable salts oresters thereof, in particular compounds according to formula (I) asdescribed herein and pharmaceutically acceptable salts thereof, moreparticularly compounds according to formula (I) as described herein.

Another embodiment of the present invention are compounds according toformula (I) as described herein, wherein

-   -   R¹ is substituted phenyl-C₁₋₆-alkyl, substituted        phenoxy-C₁₋₆-alkyl, substituted phenyl-C₂₋₆-alkenyl, substituted        pyridinyl or substituted pyridinyl-C₁₋₆-alkyl, wherein        substituted phenyl-C₁₋₆-alkyl, substituted phenoxy-C₁₋₆-alkyl,        substituted phenyl-C₂₋₆-alkenyl, substituted pyridinyl and        substituted pyridinyl-C₁₋₆-alkyl are substituted by R³, R⁴ and        R⁵;    -   Y is a —OC(O)— or —C(O)—;    -   W is —C(O)—;    -   R² is substituted phenyl or substituted pyridinyl, wherein        substituted phenyl and substituted pyridinyl are substituted by        R⁶, R⁷ and R⁸;    -   R³ is halo-C₁₋₆-alkoxy, C₁₋₆-alkylcarbonylamino or        tetrahydropyranyl-C₁₋₆-alkoxy;    -   R⁴ is H, C₁₋₆-alkyl or C ₃₋₈-cycloalkyl;    -   R⁵ is H;    -   R⁶ is aminosulfonyl;    -   R⁷ and R⁸ are independently selected from H and halogen;    -   R⁹ is C₁₋₆-alkyl, C₁₋₆-alkoxy or halogen;    -   m,n, p and q are 1;    -   or pharmaceutically acceptable salts.

A particular embodiment of the present invention are compounds accordingto formula (I) as described herein, wherein R¹ is substitutedphenyl-C₁₋₆-alkyl, substituted phenoxy-C₁₋₆-alkyl, substitutedphenyl-C₂₋₆-alkenyl, substituted pyridinyl or substitutedpyridinyl-C₁₋₆-alkyl, wherein substituted phenyl-C₁₋₆-alkyl, substitutedphenoxy-C₁₋₆-alkyl, substituted phenyl-C₂₋₆-alkenyl, substitutedpyridinyl and substituted pyridinyl-C₁₋₆-alkyl are substituted by R³, R⁴and R⁵.

A further particular embodiment of the present invention are compoundsaccording to formula (I) as described herein, wherein R¹ is substitutedpyridinyl or substituted pyridinyl-C₁₋₆-alkyl, wherein substitutedpyridinyl and substituted pyridinyl-C₁₋₆-alkyl are substituted by R³, R⁴and R⁵.

A particular embodiment of the present invention are compounds accordingto formula (I) as described herein, wherein Y is —C(O)—.

A particular embodiment of the present invention are compounds accordingto formula (I) as described herein, wherein R² is substituted phenyl orsubstituted pyridinyl, wherein substituted phenyl and substitutedpyridinyl are substituted by R⁶, R⁷ and R⁸.

A particular embodiment of the present invention are compounds accordingto formula (I) as described herein, wherein R³ is halo-C₁₋₆-alkoxy,C₁₋₆-alkylcarbonylamino or tetrahydropyranyl-C₁₋₆-alkoxy.

A further particular embodiment of the present invention are compoundsaccording to formula (I) as described herein, wherein R³ istetrahydropyranyl-C₁₋₆-alkoxy.

A particular embodiment of the present invention are compounds accordingto formula (I) as described herein, wherein R⁴ is H, C₁₋₆-alkyl orC₃₋₈-cycloalkyl.

A further particular embodiment of the present invention are compoundsaccording to formula (I) as described herein, wherein R⁴ isC₃₋₈-cycloalkyl.

A particular embodiment of the present invention are compounds accordingto formula (I) as described herein, wherein R⁵ is H.

A particular embodiment of the present invention are compounds accordingto formula (I) as described herein, wherein R⁷ and R⁸ are independentlyselected from H and halogen.

A further particular embodiment of the present invention are compoundsaccording to formula (I) as described herein, wherein R⁷ is H orhalogen.

A further particular embodiment of the present invention are compoundsaccording to formula (I) as described herein, wherein R⁸ is H.

A particular embodiment of the present invention are compounds accordingto formula (I) as described herein, wherein R⁹ is halogen orC₁₋₆-alkoxy.

A particular embodiment of the present invention are compounds accordingto formula (I) as described herein, wherein m, n, p and q are 1.

A more particular embodiment of the present invention are compoundsaccording to formula (I) as described herein, wherein

-   -   R¹ is substituted pyridinyl or substituted pyridinyl-C₁₋₆-alkyl,        wherein substituted pyridinyl and substituted        pyridinyl-C₁₋₆-alkyl are substituted by R³, R⁴ and R⁵;    -   Y is —C(O)—;    -   W is —C(O)—;    -   R² is substituted phenyl or substituted pyridinyl, wherein        substituted phenyl and substituted pyridinyl are substituted by        R⁶, R⁷ and R⁸;    -   R³ is tetrahydropyranyl-C₁₋₆-alkoxy;    -   R⁴ is C₃₋₈-cycloalkyl;    -   R⁵ is H;    -   R⁶ is aminosulfonyl;    -   R⁷ is H or halogen;    -   R⁸ is H;    -   R⁹ is halogen or C₁₋₆-alkoxy;    -   m, n, p and q are 1    -   or pharmaceutically acceptable salts.

A particular embodiment of the present invention are compounds accordingto formula I(a) as described herein,

wherein

-   -   R¹ is substituted phenyl-C₁₋₆-alkyl, substituted        phenoxy-C₁₋₆-alkyl, substituted phenyl-C₂₋₆-alkenyl, substituted        pyridinyl or substituted pyridinyl-C₁₋₆-alkyl, wherein        substituted phenyl-C₁₋₆-alkyl, substituted phenoxy-C₁₋₆-alkyl,        substituted phenyl-C₂₋₆-alkenyl, substituted pyridinyl and        substituted pyridinyl-C₁₋₆-alkyl are substituted by R³, R⁴ and        R⁵;    -   Y is a —OC(O)— or —C(O)—;    -   W is —C(O)—;    -   R² is substituted phenyl or substituted pyridinyl, wherein        substituted phenyl and substituted pyridinyl are substituted by        R⁶, R⁷ and R⁸;    -   R³ is halo-C₁₋₆-alkoxy, C₁₋₆-alkylcarbonylamino or        tetrahydropyranyl-C₁₋₆-alkoxy;    -   R⁴ is H, C₁₋₆-alkyl or C ₃₋₈-cycloalkyl;    -   R⁵ is H;    -   R⁷ and R⁸ are independently selected from H and halogen;    -   R⁹ is C₁₋₆-alkyl, C₁₋₆-alkoxy or halogen;    -   m,n, p and q are 1;    -   or pharmaceutically acceptable salts.

A further particular embodiment of the present invention are compoundsaccording to formula I(b) as described herein,

wherein

-   -   R¹ is substituted pyridinyl or substituted pyridinyl-C₁₋₆-alkyl,        wherein substituted pyridinyl and substituted        pyridinyl-C₁₋₆-alkyl are substituted by R³, R⁴ and R⁵;    -   Y is —C(O)—;    -   W is —C(O)—;    -   R² is substituted phenyl or substituted pyridinyl, wherein        substituted phenyl and substituted pyridinyl are substituted by        R⁶, R⁷ and R⁸;    -   R³ is tetrahydropyranyl-C₁₋₆-alkoxy;    -   R⁴ is C₃₋₈-cycloalkyl;    -   R⁵ is H;    -   R⁷ is H or halogen;    -   R⁸ is H;    -   R⁹ is halogen or C₁₋₆-alkoxy;    -   m, n, p and q are 1    -   or pharmaceutically acceptable salts.

Particular examples of compounds of formula (I) as described herein areselected from

-   -   trans-5-(2-fluoro-4-sulfamoyl-benzoyl)-3a-methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic        acid 3-(2,2-dimethyl -propionyl amino)-5-trifluoromethyl        -pyridin-2-ylmethyl ester;    -   trans-4-[3a-methoxy-2-[3-[4-(trifluoromethoxy)phenyl]propanoyl]-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-5-carbonyl]-3-fluorobenzenesulfonamide;    -   trans-4-[5-[2-cyclopropyl-6-(oxan-4-ylmethoxy)pyridine-4-carbonyl]-3a-methoxy-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-2-carbonyl]-3-fluorobenzenesulfonamide;    -   trans-5-(4-sulfamoyl-benzoyl)-3a-methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic        acid        3-(2,2-dimethyl-propionylamino)-5-trifluoromethyl-pyridin-2-ylmethyl        ester;    -   trans-5-(4-sulfamoyl-benzoyl)-3a-fluoro-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic        acid 4-trifluoromethoxy-benzyl ester;    -   trans-5-(4-sulfamoyl-benzoyl)-3a-methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic        acid 4-trifluoromethoxy-benzyl ester;    -   trans-3a-methyl-5-(4-sulfamoyl-benzoyl)-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic        acid 4-trifluoromethoxy-benzyl ester;    -   trans-5-(5-sulfamoylpyridine-2-carbonyl)-3a-methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic        acid        3-(2,2-dimethyl-propionylamino)-5-trifluoromethyl-pyridin-2-ylmethyl        ester;    -   trans-6-[3a-methoxy-2-[3-[4-(trifluoromethoxy)phenyl]propanoyl]-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-5-carbonyl]pyridine-3-sulfonamide;    -   trans-6-[5-[2-cyclopropyl-6-(oxan-4-ylmethoxy)pyridine-4-carbonyl]-3a-methoxy-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-2-carbonyl]pyridine-3-sulfonamide;    -   trans-5-(2-fluoro-4-sulfamoyl-benzoyl)-3a-fluoro-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic        acid 4-trifluoromethoxy-benzyl ester;    -   trans-4-[3a-fluoro-2-[(E)-3-[4-(trifluoromethoxy)phenyl]prop-2-enoyl]-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-5-carbonyl]-3-fluorobenzenesulfonamide;    -   trans-4-[3a-fluoro-2-[2-[4-(trifluoromethoxy)phenoxy]acetyl]-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-5-carbonyl]-3-fluorobenzenesulfonamide;    -   trans-4-[5-[2-cyclopropyl-6-(oxan-4-ylmethoxy)pyridine-4-carbonyl]-3a-fluoro-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-2-carbonyl]-3-fluorobenzenesulfonamide;    -   trans-4-[3a-fluoro-2-[3-[4-(trifluoromethoxy)phenyl]propanoyl]-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-5-carbonyl]-3-fluorobenzenesulfonamide;    -   (+)-(3aR,        6aR)-3a-methyl-5-(4-sulfamoyl-benzoyl)-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic        acid 4-trifluoromethoxy-benzyl ester;    -   (−)-trans-5-(4-sulfamoyl-benzoyl)-3a-methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic        acid 4-trifluoromethoxy-benzyl ester;    -   (−)-trans-5-(4-sulfamoyl-benzoyl)-3a-fluoro-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic        acid 4-trifluoromethoxy-benzyl ester;    -   (−)        trans-5-(4-sulfamoyl-benzoyl)-3a-methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic        acid        3-(2,2-dimethyl-propionylamino)-5-trifluoromethyl-pyridin-2-ylmethyl        ester;    -   (−)-(3aS,6aS)-3a-methyl-5-(4-sulfamoylbenzoyl)-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic        acid 4-trifluoromethoxy-benzyl ester;    -   (+)-trans-5-(4-sulfamoyl-benzoyl)-3a-methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic        acid 4-trifluoromethoxy-benzyl ester;    -   (+)-trans-5-(4-sulfamoyl-benzoyl)-3a-fluoro-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic        acid 4-trifluoromethoxy-benzyl ester;    -   (+)-trans-5-(4-sulfamoyl-benzoyl)-3a-methoxy-hexahydro-pyrrolo[3,4-c]        pyrrole-2-carboxylic acid        3-(2,2-dimethyl-propionylamino)-5-trifluoromethyl-pyridin-2-ylmethyl        ester;    -   and pharmaceutically acceptable salts thereof.

Further particular examples of compounds of formula (I) as describedherein are selected from

-   -   trans-4-[5-[2-cyclopropyl-6-(oxan-4-ylmethoxy)pyridine-4-carbonyl]-3a-methoxy-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-2-carbonyl]-3-fluorobenzenesulfonamide;    -   trans-6-[5-[2-cyclopropyl-6-(oxan-4-ylmethoxy)pyridine-4-carbonyl]-3a-methoxy-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-2-carbonyl]pyridine-3-sulfonamide;    -   trans-4-[5-[2-cyclopropyl-6-(oxan-4-ylmethoxy)pyridine-4-carbonyl]-3a-fluoro-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-2-carbonyl]-3-fluorobenzenesulfonamide;    -   and pharmaceutically acceptable salts thereof.

Processes for the manufacture of compounds of formula (I) as describedherein are an object of the invention.

The preparation of compounds of formula (I) of the present invention maybe carried out in sequential or convergent synthetic routes. Synthesesof the invention are shown in the following general schemes. The skillsrequired for carrying out the reactions and purifications of theresulting products are known to those persons skilled in the art. Incase a mixture of enantiomers or diastereoisomers is produced during areaction, these enantiomers or diastereoisomers can be separated bymethods described herein or known to the man skilled in the art such ase.g. (chiral) chromatography or crystallization. The substituents andindices used in the following description of the processes have thesignificance given herein.

Compounds of general formula (I) can be synthesised from amine precursor1 and appropriate reagents, using methods well known in the art.

For instance, amine 1 is reacted with a suitable carboxylic acid offormula R¹—COOH (2) leading to a compound of formula (I), wherein Y is—C(O)—. The reaction is performed in the presence of a coupling agentsuch as 1,1′-carbonyldiimidazole, N,N′-dicyclohexylcarbodiimide,1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride,O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate,O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluoro-phosphate or bromo-tris-pyrrolidino-phosphoniumhexafluorophosphate, in aprotic solvents such as dichloromethane,tetrahydrofuran, N,N-dimethylformamide, N-methylpyrrolidinone andmixtures thereof at temperatures between −40° C. and 80° C. in thepresence or absence of a base such as triethylamine,diisopropylethylamine, 4-methylmorpholine and/or 4-(dimethylamino)pyridine.

Amine 1 can also be reacted with suitable acylating reagents such asacyl chlorides of formula R¹—COCl (3) to lead to compounds of formula(I), wherein Y is —C(O)—. The reaction is performed in a solvent such asdichloromethane, tetrahydrofuran, or N,N-dimethylformamide, in thepresence of a base such as triethylamine or 4-methylmorpholine, attemperatures between 0° C. and 80° C.

Alternatively, amine 1 is reacted with a suitable chloroformate ester offormula R¹—O—C(O)Cl (4), or with an imidazole-l-carboxylate ester offormula (3), leading to a compound of formula (I) wherein Y is —OC(O)—.

The reaction is performed in a suitable solvent such as dichloromethane,tetrahydrofuran, N,N-dimethylformamide, acetonitrile, acetone, water, ormixtures thereof, in the presence of a base, e. g., triethylamine,diisopropylethylamine, pyridine, potassium hydrogencarbonate, potassiumcarbonate, at temperatures between 0° C. and the boiling point of thesolvent or solvent mixture.

Chloroformate esters 4 are commercially available or can be synthesisedfrom the corresponding alcohol of formula R¹—OH, by reaction withphosgene or a phosgene equivalent (e. g., diphosgene, triphosgene), asdescribed in the literature.

Imidazole-1-carboxylate esters 5 are synthesised from the correspondingalcohols of formula R¹—OH, by reaction with 1,1′-carbonyldiimidazole.The reaction is performed at room temperature, in a solvent such asdichloromethane, tetrahydrofuran or acetonitrile. Theimidazole-1-carboxylate esters 5 are typically not isolated but directlyreacted with amines 1 as described above.

Alcohols of formula R¹—OH are commercially available or can be producedby methods described herein or known in the art.

Carboxylic acids (2) and acyl halides (3) are commercially available orcan be prepared as described herein or in the literature.

Amines of general formula 1 are synthesised from suitably protectedprecursors 6.

Suitable protective groups (PG) are tert-butoxycarbonyl orbenzyloxycarbonyl. The deprotection of intermediates 6 can be performedusing methods and reagents known in the art.

For instance, in the case where PG is benzyloxycarbonyl, thedeprotection may be performed by hydrogenation at pressures between 1bar and 100 bar, in the presence of a suitable catalyst such aspalladium on activated charcoal, at temperatures between 20° C. and 150°C. in solvents such as methanol or ethanol.

Alternatively, in the case where PG is tert-butoxycarbonyl, thedeprotection may be performed in the presence of a suitable acid, e. g,hydrochloric acid or trifluoroacetic acid, in a solvent such as water,2-propanol, dichloromethane, or 1,4-dioxane at temperatures between 0°C. and 30° C.

Intermediates 6 can be produced from amine precursors of general formula7 by reaction with appropriate reagents, using methods known in the art.

For instance, 7 is reacted with alkylating agents of general formulaX—CR⁷R⁸R² (8) where X is a leaving group such as Cl, Br, I, or OSO₂CH₃,leading to 6, wherein W is —CR⁷R⁸—. This reaction is performed in asolvent such as tetrahydrofuran or N,N-dimethylformamide, in thepresence of a base, e. g. triethylamine or potassium carbonate, attemperatures between 0° C. and 100° C.

Alternatively, for compounds of formula 6, wherein W is —CR⁷R⁸, R⁷ ishydrogen, alkyl or cycloalkyl, and R⁸ is H, amine 7 is reacted withaldehydes or ketones of general formula R⁷—C(O)R² (9) in a reductiveamination reaction, leading to 6. This reaction is performed in thepresence of a suitable reducing agent, e. g., sodium borohydride orsodium triacetoxyboro-hydride, in a solvent such as methanol, aceticacid, tetrahydrofuran, 1,2-dichloroethane or mixtures thereof, attemperatures between 0° C. and 50° C.

Alternatively, amine 7 is reacted with a suitable carboxylic acid offormula R²COOH (10), leading to compounds of formula 6, wherein W is—C(O)—. The reaction is performed in the presence of a coupling agentsuch as 1,1′-carbonyldiimidazole, N,N′-dicyclohexylcarbodiimide,1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride,O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate,O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluoro-phosphate or bromo-tris-pyrrolidino-phosphoniumhexafluorophosphate, in aprotic solvents such as dichloromethane,tetrahydrofuran, N,N-dimethylformamide, N-methylpyrrolidinone andmixtures thereof at temperatures between −40° C. and 80° C. in thepresence or absence of a base such as triethylamine,diisopropylethylamine, 4-methylmorpholine and/or 4-(dimethylamino)pyridine.

Alternatively, amine 7 is reacted with a suitable sulfonyl chloride offormula R²—SO₂Cl (11), leading to compounds of formula 6, wherein W is—S(O₂)—. The reaction is performed in a suitable solvent such asdichloromethane, tetrahydrofuran, N,N-dimethyl-formamide, acetonitrile,acetone, water, or mixtures thereof, in the presence of a base, e. g.triethylamine, diisopropylethylamine, pyridine, potassiumhydrogencarbonate, potassium carbonate, at temperatures between 0° C.and the boiling point of the solvent or solvent mixture.

Amines 7, alkylating agents 8, aldehydes/ketones 9, carboxylic acids 10,and sulfonyl chlorides 11 are commercially available or can besynthesised as described herein or in the literature.

Compounds of formula (I), can be produced from amine precursors ofgeneral formula 12 by reaction with appropriate reagents, using methodsknown in the art.

For instance, an amine of formula 12 is reacted with alkylating agentsof general formula X—CR⁷R⁸—R² (8) where X is a leaving group such as Cl,Br, I, or OSO₂CH₃, leading to compounds of formula (I), wherein W is—CR⁷R⁸—. This reaction is performed in a solvent such as tetrahydrofuranor N,N-dimethylformamide, in the presence of a base, e. g.,triethylamine or potassium carbonate, at temperatures between 0° C. and100° C.

Alternatively, an amine of formula 12 is reacted with aldehydes orketones of general formula R⁷C(O)—R² (9) in a reductive aminationreaction, leading to compounds of formula (I) wherein W is —CR⁷R⁸—, R⁷is hydrogen, alkyl or cycloalkyl, and R⁸ is H. This reaction isperformed in the presence of a suitable reducing agent, e. g. sodiumborohydride or sodium triacetoxyborohydride, in a solvent such asmethanol, acetic acid, tetrahydrofuran, 1,2-dichloroethane or mixturesthereof, at temperatures between 0° C. and 50° C.

Alternatively, amine 12 is reacted with a suitable carboxylic acid offormula R²—COOH (10), leading to compounds of formula (I) wherein W is—C(O)—. The reaction is performed in the presence of a coupling agentsuch as 1,1′-carbonyldiimidazole, N,N′-dicyclohexylcarbodiimide,1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride,O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate,O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluoro-phosphate or bromo-tris-pyrrolidino-phosphoniumhexafluorophosphate, in aprotic solvents such as dichloromethane,tetrahydrofuran, N,N-dimethylformamide, N-methylpyrrolidinone andmixtures thereof at temperatures between −40° C. and 80° C. in thepresence or absence of a base such as triethylamine,diisopropylethylamine, 4-methylmorpholine and/or4-(dimethylamino)pyridine.

Alternatively, amine 12 is reacted with a suitable sulfonyl chloride offormula R²—SO₂Cl (11), leading to (I) wherein W is —S(O₂)—. The reactionis performed in a suitable solvent such as dichloromethane,tetrahydrofuran, N,N-dimethylformamide, acetonitrile, acetone, water, ormixtures thereof, in the presence of a base, e. g. triethylamine,diisopropylethylamine, pyridine, potassium hydrogencarbonate, potassiumcarbonate, at temperatures between 0° C. and the boiling point of thesolvent or solvent mixture.

Amines 12 can be synthesised from their tert-butyl carbamate derivativesof formula 13 by carbamate deprotection. The deprotection may beperformed in the presence of a suitable acid, e.g., hydrochloric acid ortrifluoroacetic acid, in a solvent such as water, 2-propanol,dichloromethane, or 1,4-dioxane, at temperatures between 0° C. and 30°C.

tert-Butyl carbamates 13 can be synthesised from amine precursors offormula 14 and appropriate reagents, using methods well known in theart.

For instance, amine 14 is reacted with a suitable carboxylic acid offormula R¹—COOH (2) leading to compounds of formula 13, wherein Y is—C(O)—. The reaction is performed in the presence of a coupling agentsuch as 1,1′-carbonyldiimidazole, N,N′-dicyclohexylcarbodiimide,1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride,O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate,O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluoro-phosphate or bromo-tris-pyrrolidino-phosphoniumhexafluorophosphate, in aprotic solvents such as dichloromethane,tetrahydrofuran, N,N-dimethylformamide, N-methylpyrrolidinone andmixtures thereof at temperatures between −40° C. and 80° C. in thepresence or absence of a base such as triethylamine,diisopropylethylamine, 4-methylmorpholine and/or 4-(dimethylamino)pyridine.

Amine 14 can also be reacted with suitable acylating reagents, such asacyl chlorides of formula R¹—COCl (3) to provide compounds of formula13, wherein Y is —C(O)—. The reaction is performed in a solvent such asdichloromethane, tetrahydrofuran, or N,N-dimethylformamide, in thepresence of a base such as triethylamine or 4-methylmorpholine, attemperatures between 0° C. and 80° C.

Alternatively, amine 14 is reacted with a suitable chloroformate esterof formula R¹—O—C(O)Cl (4), or with an imidazole-1-carboxylate ester offormula 5, leading to a compound of formula 13, wherein Y is —OC(O)—.The reaction is performed in a suitable solvent such as dichloromethane,tetrahydrofuran, N,N-dimethylformamide, acetonitrile, acetone, water, ormixtures thereof, in the presence of a base, e. g., triethylamine,diisopropylethylamine, pyridine, potassium hydrogencarbonate, potassiumcarbonate, at temperatures between 0° C. and the boiling point of thesolvent or solvent mixture.

Alternatively, amine 14 can be reacted with a phosgene or a phosgeneequivalent (e. g., triphosgene) to the correspondingN-chlorocarbonylamine 14A, in the presence of a base (e. g., pyridine)in a suitable solvent, e. g., dichloromethane, at temperatures between78° C. and +20° C. N-Chlorocarbonylamine 14A is then reacted withalcohol of formula R¹—OH, leading to a compound of formula 13, wherein Yis —OC(O)—. This reaction is performed in a suitable solvent (e. g.,acetonitrile of dichloromethane) in the presence of a suitable base (e.g., sodium hydride, pyridine or polystyrene-bound2-tert-butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphorine),at temperatures between 20° C. and the boiling point of the solvent.

Amines of formula 22 are commercially available or can be produced asdescribed herein or in the literature.

Also an embodiment of the present invention is a process to prepare acompound of formula (I) as defined above comprising the reaction of acompound of formula (II) in the presence of a compound of formula (III);

wherein R¹, R², R⁹, m, n, p and q are as defined above and W is —C(O)—.

In particular, in the presence of a coupling agent such as1,1′-carbonyldiimidazole, N,N′-dicyclohexylcarbodiimide,1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride,O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate,O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluoro-phosphate or bromo-tris-pyrrolidino-phosphoniumhexafluorophosphate, particularlyO-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluoro-phosphate, in an aprotic solvent such as dichloromethane,tetrahydrofuran, N,N-dimethylformamide, N-methylpyrrolidinone andmixtures thereof, particularly N,N-dimethylformamide, in the presence orabsence of a base such as triethylamine, diisopropylethylamine,4-methylmorpholine and/or 4-(dimethylamino)pyridine, particularly in thepresence of 4-methylmorpholine and at a temperature comprised between−78° C. and reflux, particularly between −10° C. and room temperature.

Also an object of the present invention is a compound according toformula (I) as described herein for use as a therapeutically activesubstance.

Likewise an object of the present invention is a pharmaceuticalcomposition comprising a compound according to formula (I) as describedherein and a therapeutically inert carrier.

A particular embodiment of the present invention is a compound accordingto formula (I) as described herein for the treatment or prophylaxis ofocular conditions, particularly glaucoma.

The present invention also relates to the use of a compound according toformula (I) as described herein for the preparation of a medicament forthe treatment or prophylaxis of ocular conditions, particularlyglaucoma.

Also an object of the invention is a method for the treatment orprophylaxis of ocular conditions, particularly glaucoma, which methodcomprises administering an effective amount of a compound according toformula (I) as described herein.

Inflammatory conditions include, but are not limited to, arthritis,osteoarthritis, multiple sclerosis, systemic lupus erythematodes,inflammatory bowel disease, abnormal evacuation disorder and the like aswell as inflammatory airways diseases such as idiopathic pulmonaryfibrosis (IPF), chronic obstructive pulmonary disease (COPD) or chronicasthma bronchiale.

Further conditions of the respiratory system include, but are notlimited to, other diffuse parenchymal lung diseases of differentetiologies including iatrogenic drug-induced fibrosis, occupationaland/or environmental induced fibrosis, systemic diseases andvasculitides, granulomatous diseases (sarcoidosis, hypersensitivitypneumonia), collagen vascular disease, alveolar proteinosis, Langerhanscell granulomatosis, lymphangioleiomyomatosis, inherited diseases(Hermansky-Pudlak Syndrome, tuberous sclerosis, neurofibromatosis,metabolic storage disorders, familial interstitial lung disease),radiation induced fibrosis, silicosis, asbestos induced pulmonaryfibrosis or acute respiratory distress syndrome (ARDS).

Conditions of the nervous system include, but are not limited to,neuropathic pain, schizophrenia, neuro-inflammation (e.g. astrogliosis),peripheral and/or autonomic (diabetic) neuropathies and the like.

Vascular conditions include, but are not limited to, atherosclerosis,thrombotic vascular disease as well as thrombotic microangiopathies,proliferative arteriopathy (such as swollen myointimal cells surroundedby mucinous extracellular matrix and nodular thickening),atherosclerosis, decreased vascular compliance (such as stiffness,reduced ventricular compliance and reduced vascular compliance),endothelial dysfunction and the like.

Cardiovascular conditions include, but are not limited to, acutecoronary syndrome, coronary heart disease, myocardial infarction,arterial and pulmonary hypertension, cardiac arrhythmia such as atrialfibrillation, stroke and other vascular damage.

Fibrotic diseases include, but are not limited to myocardial andvascular fibrosis, pulmonary fibrosis, skin fibrosis, scleroderma andencapsulating peritonitis.

Cancer and cancer metastasis include, but are not limited to, breastcancer, ovarian cancer, lung cancer, prostate cancer, mesothelioma,glioma, gastrointestinal cancers and progression and metastaticaggressiveness thereof.

Ocular conditions include, but are not limited to, proliferative andnon-proliferative (diabetic) retinopathy, dry and wet age-relatedmacular degeneration (AMD), macular edema, central arterial /venousocclusion, traumatic injury, glaucoma and the like. Particularly, theocular condition is glaucoma.

Metabolic conditions include, but are not limited to, obesity anddiabetes.

Also an embodiment of the present invention are compounds of formula (I)as described herein, when manufactured according to any one of thedescribed processes.

Assay Procedures

Production of Human Full Length ATX, with and without His Tag

Autotaxin (ATX-ENPP2) cloning: cDNA was prepared from commercial humanhematopoietic cells total RNA and used as template in overlapping PCR togenerate a full length human ENPP2 ORF with or without a 3′-6× His tag.These full length inserts were cloned into the pcDNA3.1V5-His TOPO(Invitrogen) vector. The DNA sequences of several single clones wereverified. The DNA from a correct full length clone was used to transfectHek293 cells for verification of protein expression. The sequence of theencoded ENPP2 conforms to Swissprot entry Q13822, with or without theadditional C-terminal 6× His tag.

ATX Fermentation: Recombinant protein was produced by large-scaletransient transfection in 20 L controlled stirred tank bioreactors(Sartorius). During cell growth and transfection, temperature, stirrerspeed, pH and dissolved oxygen concentration were maintained at 37° C.,120 rpm, 7.1 and 30% DO, respectively. FreeStyle 293-F cells(Invitrogen) were cultivated in suspension in FreeStyle 293 medium(Invitrogen) and transfected at ca. 1-1.5×10E6 cells/mL with aboveplasmid DNAs using X-tremeGENE Ro-1539 (commercial product, RocheDiagnostics) as complexing agent. Cells were fed a concentrated nutrientsolution (J Immunol Methods 194 (1996), 19, 1-199 (page 193)) andinduced by sodium butyrate (2 mM) at 72 h post-transfection andharvested at 96 h post-transfection. Expression was analyzed by WesternBlot, enzymatic assay and/or analytical IMAC chromatography. Aftercooling the cell suspension to 4° C. in a flow-through heat exchanger,cell separation and sterile filtration of supernatant was performed byfiltration through Zeta Plus 60M02 E16 (Cuno) and Sartopore 2 XLG(Sartorius) filter units. The supernatant was stored at 4° C. prior topurification.

ATX Purification: 20 liter of culture supernatant were conditioned forultrafiltration by adding Brij 35 to a final concentration of 0.02% andby adjusting the pH to 7.0 using 1 M HCl. Then the supernatant was firstmicrofiltred through a 0.2 □m Ultran-Pilot Open Channel PES filter(Whatman) and afterwards concentrated to 1 liter through an Ultran-PilotScreen Channel PES filter with 30 kDa MWCO (Whatman). Prior to IMACchromatography, NiSO₄ was added to a final concentration of 1 mM. Thecleared supernatant was then applied to a HisTrap column (GE Healthcare)previously equilibrated in 50 mM Na₂HPO₄ pH 7.0, 0.5 M NaCl, 10%glycerol, 0.3% CHAPS, 0.02% NaN₃. The column was washed stepwise withthe same buffer containing 20 mM, 40 mM and 50 mM imidazole,respectively. The protein was subsequently eluted using a lineargradient to 0.5 M imidazole in 15 column volumes. ATX containingfractions were pooled and concentrated using an Amicon cell equippedwith a 30 kDa PES filter membrane. The protein was further purified bysize exclusion chromatography on Superdex S-200 prep grade (XK 26/100)(GE Healthcare) in 20 mM BICINE pH 8.5, 0.15 M NaCl, 10% glycerol, 0.3%CHAPS, 0.02% NaN₃. Final yield of protein after purification was 5-10 mgATX per liter of culture supernatant. The protein was stored at −80° C.

Human ATX Enzyme Inhibition Assay

ATX inhibition was measured by a fluorescence quenching assay using aspecifically labeled substrate analogue (MR121 substrate). To obtainthis MR121 substrate, BOC and TBS protected 6-amino-hexanoic acid(R)-3-({2-[3-(2-{2-[2-(2-amino-ethoxy)-ethoxy]-ethoxy}-ethoxy)-propionylamino]-ethoxy}-hydroxy-phosphoryloxy)-2-hydroxy-propylester (Ferguson et al., Org Lett 2006, 8 (10), 2023) was labeled withMR121 fluorophore (CAS 185308-24-1,1-(3-carboxypropyl)-11-ethyl-1,2,3,4,8,9,10, 11-octahydro-dipyrido[3,2-b:2′,3′-i]phenoxazin-13-ium) on the free amine of the ethanolamine sideand then, after deprotection, subsequently with tryptophan on the sideof the aminohexanoic acid.

Assay working solutions were made as follows:

-   Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl₂, 1    mM MgCl₂, 0.01% Triton-X-100, pH 8.0;-   ATX solution: ATX (human His-tagged) stock solution (1.08 mg/mL in    20 mM bicine, pH 8.5, 0.15 M NaCl, 10% glycerol, 0.3% CHAPS, 0.02%    NaN₃), diluted to 1.4-2.5× final concentration in assay buffer;-   MR121 substrate solution: MR121 substrate stock solution (800 μM    MR121 substrate in DMSO), diluted to 2-5× final concentration in    assay buffer.

Test compounds (10 mM stock in DMSO, 8 μL) were obtained in 384 wellsample plates (Corning Costar #3655) and diluted with 8 μL DMSO.Row-wise serial dilutions were made by transferring 8 μL cpd solution tothe next row up to row O. The compound and control solutions were mixedfive times and 2 μL were transferred to 384 well assay plates (CorningCostar #3702). Then, 15 μL of 41.7 nM ATX solution was added (30 nMfinal concentration), mixed five times and then incubated for 15 minutesat 30° C. 10 μL of MR121 substrate solution was added (1 μM finalconcentration), mixed 30 times and then incubated for 15 minutes at 30°C. Fluorescence was then measured every 2 minutes for 1 hour (PerkinElmer plate: vision multimode reader); light intensity: 2.5%; exp. time:1.4 sec, Filter: Fluo_630/690 nm) and IC₅₀ values were calculated fromthese readouts.

Human Carbonic Anhydrase-II Inhibition Assay

Human carbonic anhydrase II (hCA-II) inhibition was measured by anabsorbance method using 4-nitrophenyl acetate (4-NPA) as its substrate.4-NPA can be catalyzed by active hCA II via a zinc-hydroxide mechanism.The nitrophenolate in the products can be ionized to generate a brightyellow anion with high absorbance at 348 to 400 nm, as reported in theliterature (Armstrong et al., J. Biol. Chem. 1966, 241, 5137-5149).OD340 nm was chosen for detecting hCA II substrate conversion.

Assay working solutions were made as follows:

-   Assay buffer: 50 mM MOPS, 33 mM Na2SO4, 1 mM EDTA, 0.5 mg/ml BSA, pH    7.5;-   Enzyme solution: hCA-II (human, full length) stock solution (1.0    mg/mL in 20 mM HEPES, 50 mM NaCl, pH 7.4), diluted to 2133× final    concentration in assay buffer;

4-NPA substrate solution: 4-NPA substrate stock solution (250 mM inDMSO, stored at −20° C.), diluted to 50× final concentration indeionized water.

Test compounds (10 mM stock in DMSO, 100 μL) were obtained in 96-wellsample plates (Corning Costar #3655) and diluted to 0.5 mM. Column-wiseserial dilutions were made by transferring 20 μL compound solutions tothe next column, from column 3 up to 22. After this, 1.2 μL weretransferred to 384 well assay plates (Corning Costar # 3701). Then 30 μLof 16 nM hCA II solution was added (8 nM final concentration), mixedfive times. 30 μL of 4-NPA substrate solution was added (2.5 mM finalconcentration), mixed five times. Absorbance at 340 nm was then measuredimmediately as time zero. The assay plates were incubated at roomtemperature for 1 hour and then measured as time 1 hour (Perkin ElmerEnVision 2103; Filter: Photometric 340; Light intensity 60%; Number offlashes: 10). IC₅₀ values and K_(i) values were calculated from thesereadouts.

ATX CA-II IC50 IC50 Ex (μM) (μM) 1.00 0.008 0.005 1.01 0.01 0.008 1.020.006 0.01 1.03 0.006 1.04 0.003 1.05 0.02 1.06 0.006 1.07 0.006 0.0131.08 0.017 0.018 1.09 0.01 0.01 2.00 0.007 0.006 3.00 0.005 0.009 3.010.007 0.006 3.02 0.008 0.006 3.03 0.004 0.006 4.00 0.006 0.095 4.010.013 0.018 4.02 0.008 0.01 4.03 0.011 0.013 5.00 0.007 0.038 5.01 0.0060.027 5.02 0.004 0.015 5.03 0.013 0.02

Compounds of formula (I) and their pharmaceutically acceptable salts oresters thereof as described herein have IC₅₀ values between 0.00001 μMand 1000 μM, particular compounds have IC₅₀ values between 0.0005 μM and500 μM, further particular compounds have IC₅₀ values between 0.0005 μMand 50 μM, more particular compounds have IC₅₀ values between 0.0005 μMand 5 μM. These results have been obtained by using the enzymatic assaydescribed above.

The compounds of formula (I) and their pharmaceutically acceptable saltscan be used as medicaments (e.g. in the form of pharmaceuticalpreparations). The pharmaceutical preparations can be administeredinternally, such as orally (e.g. in the form of tablets, coated tablets,drages, hard and soft gelatin capsules, solutions, emulsions orsuspensions), nasally (e.g. in the form of nasal sprays), rectally (e.g.in the form of suppositories) or topical ocularly (e.g. in the form ofsolutions, ointments, gels or water soluble polymeric inserts). However,the administration can also be effected parenterally, such asintramuscularly, intravenously, or intraocularly (e.g. in the form ofsterile injection solutions).

The compounds of formula (I) and their pharmaceutically acceptable saltscan be processed with pharmaceutically inert, inorganic or organicadjuvants for the production of tablets, coated tablets, dragees,hardgelatin capsules, injection solutions or topical formulations Lactose,corn starch or derivatives thereof, talc, stearic acid or its salts etc.can be used, for example, as such adjuvants for tablets, drages and hardgelatin capsules.

Suitable adjuvants for soft gelatin capsules, are, for example,vegetable oils, waxes, fats, semi-solid substances and liquid polyols,etc.

Suitable adjuvants for the production of solutions and syrups are, forexample, water, polyols, saccharose, invert sugar, glucose, etc.

Suitable adjuvants for injection solutions are, for example, water,alcohols, polyols, glycerol, vegetable oils, etc.

Suitable adjuvants for suppositories are, for example, natural orhardened oils, waxes, fats, semi-solid or liquid polyols, etc.

Suitable adjuvants for topical ocular formulations are, for example,cyclodextrins, mannitol or many other carriers and excipients known inthe art.

Moreover, the pharmaceutical preparations can contain preservatives,solubilizers, viscosity-increasing substances, stabilizers, wettingagents, emulsifiers, sweeteners, colorants, flavorants, salts forvarying the osmotic pressure, buffers, masking agents or antioxidants.They can also contain still other therapeutically valuable substances.

The dosage can vary in wide limits and will, of course, be fitted to theindividual requirements in each particular case. In general, in the caseof oral administration a daily dosage of about 0.1 mg to 20 mg per kgbody weight, preferably about 0.5 mg to 4 mg per kg body weight (e.g.about 300 mg per person), divided into preferably 1-3 individual doses,which can consist, for example, of the same amounts, should it beappropriate. In the case of topical administration, the formulation cancontain 0.001% to 15% by weight of medicament and the required dose,which can be between 0.1 and 25 mg in can be administered either bysingle dose per day or per week, or by multiple doses (2 to 4) per day,or by multiple doses per week It will, however, be clear that the upperor lower limit given herein can be exceeded when this is shown to beindicated.

The invention is illustrated hereinafter by Examples, which have nolimiting character.

In case the preparative examples are obtained as a mixture ofenantiomers, the pure enantiomers can be obtained by methods describedherein or by methods known to those skilled in the art, such as e.g.chiral chromatography or crystallization.

EXAMPLES

All examples and intermediates were prepared under nitrogen atmosphereif not specified otherwise.

Abbreviations: aq.=aqueous; CAS-RN=Chemical Abstracts Service RegistryNumber; HPLC=high performance liquid chromatography; MS=mass spectrum;PS-BEMP=polystyrene-bound2-tert-butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphorine;sat.=saturated

Example 1trans-5-(2-Fluoro-4-sulfamoyl-benzoyl)-3a-methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylicacid3-(2,2-dimethyl-propionylamino)-5-trifluoromethyl-pyridin-2-ylmethylester

To a solution oftrans-3a-methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid3-(2,2-dimethyl-propionylamino)-5-trifluoromethyl-pyridin-2-ylmethylester dihydrochloride (intermediate 5; 96 mg, 186 μmol),4-methylmorpholine (113 mg, 1.11 mmol) and 2-fluoro-4-sulfamoylbenzoicacid (CAS-RN 714968-42-0; 42.8 mg, 186 μmol) in N,N-dimethylformamide (3mL) was added O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluoro-phosphate (70.6 mg, 186 μmol) at room temperature, then after18 h the reaction mixture was partitioned sat. aq. sodium hydrogencarbonate solution and ethyl acetate/2-methyltetrahydrofuran 4:1. Theorganic layer was washed with sat. aq. ammonium chloride solution andbrine, dried over magnesium sulfate, filtered and evaporated.Chromatography (silica gel; gradient dichloromethane todichloromethane/methanol/25% aq. ammonia solution 90:10:0.25 affordedthe title compound (107 mg, 80%). White solid, MS: 646.2 (M+H)⁺.

The following examples were produced in analogy to example 1, replacingtrans-3a-methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid3-(2,2-dimethyl-propionylamino)-5-trifluoromethyl-pyridin-2-ylmethylester dihydrochloride by the appropriate amine and2-fluoro-4-sulfamoylbenzoic acid by the appropriate carboxylic acid.

Ex. Systematic Name Amine/Carboxylic acid MS, m/e 1.01

trans-1-(3a- methoxyhexahydropyrrolo[3,4- c]pyrrol-2(1H)-yl)-3-(4-(trifluoromethoxy)phenyl)propan-1- one dihydrochloride (intermediate6.01)/2-fluoro-4-sulfamoylbenzoic acid (CAS-RN 714968-42-0) 560.2 (M +H)⁺ 1.02

trans-(2-cyclopropyl-6-((tetrahydro- 2H-pyran-4-yl)methoxy)pyridin-4-yl)3a-methoxyhexahydropyrrolo[3,4- c]pyrrol-2(1H)-yl)methanonedihydrochloride (intermediate 6)/2- fluoro-4-sulfamoylbenzoic acid(CAS-RN 714968-42-0) 603.3 (M + H)⁺ 1.03

trans-3a-methoxy-hexahydro- pyrrolo[3,4-c]pyrrole-2-carboxylic acid3-(2,2-dimethyl- propionylamino)-5-trifluoromethyl- pyridin-2-ylmethylester dihydrochloride (intermediate 5)/4- sulfamoylbenzoic acid (CAS-RN138- 41-0) 628.2 (M + H)⁺ 1.04

trans-3a-fluoro-hexahydro- pyrrolo[3,4-c]pyrrole-2-carboxylic acid4-trifluoromethoxy-benzyl ester (intermediate 4.01)/4- sulfamoylbenzoicacid (CAS-RN 138- 41-0) 530.3 (M − H)⁻ 1.05

trans-3a-fluoro-hexahydro- pyrrolo[3,4-c]pyrrole-2-carboxylic acid4-trifluoromethoxy-benzyl ester (intermediate 4.01)/4- sulfamoylbenzoicacid (CAS-RN 138- 41-0) 544.2 (M + H)⁺ 1.06

trans-3a-methyl-hexahydro- pyrrolo[3,4-c]pyrrole-2-carboxylic acid4-trifluoromethoxy-benzyl ester hydrochloride (intermediate 4)/4-sulfamoylbenzoic acid (CAS-RN 138- 41-0) 528.2 (M + H)⁺ 1.07

trans-3a-methoxy-hexahydro- pyrrolo[3,4-c]pyrrole-2-carboxylic acid3-(2,2-dimethyl- propionylamino)-5-trifluoromethyl- pyridin-2-ylmethylester dihydrochloride (intermediate 5)/5- sulfamoylpicolinic acid(CAS-RN 1308677-67-9) 629.2 (M + H)⁺ 1.08

trans-1-(3a- methoxyhexahydropyrrolo[3,4- c]pyrrol-2(1H)-yl)-3-(4-(trifluoromethoxy)phenyl)propan-1- one dihydrochloride (intermediate6.01)/5-sulfamoylpicolinic acid (CAS-RN 1308677-67-9) 543.1 (M + H)⁺1.09

trans-(2-cyclopropyl-6-((tetrahydro- 2H-pyran-4-yl)methoxy)pyridin-4-yl)3a-methoxyhexahydropyrrolo[3,4- c]pyrrol-2(1H)-yl)methanonedihydrochloride (intermediate 6)/5- sulfamoylpicolinic acid (CAS-RN1308677-67-9) 586.2 (M + H)⁺

Example 2trans-5-(2-Fluoro-4-sulfamoyl-benzoyl)-3a-fluoro-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylicacid 4-trifluoromethoxy-benzyl ester

To a solution of (4-(trifluoromethoxy)phenyl)methanol (26.1 mg, 136μmol) in acetonitrile (5 mL) was added 1,1′-carbonyldiimidazole (22 mg,136 μmol) and the reaction mixture was heated at 50° C. for 2 h, thentriethylamine (68.8 mg 680 μmol) and3-fluoro-4-(trans-3a-fluorooctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzenesulfonamidehydrochloride (50 mg, 136 μmol) were added and the reaction mixture washeated at reflux for another 15 h. After cooling the reaction mixturewas partitioned between ethyl acetate and sat. aq. sodium hydrogencarbonate solution. The organic layer was washed with sat. aq. ammoniumchloride solution and brine, dried over magnesium sulfate, filtered andevaporated. Chromatography (silica gel; gradient dichloromethane todichloromethane/methanol/25% aq. ammonia solution 90:10:0.25 affordedthe title compound (59 mg, 79%). White foam, MS: 550.1 (M+H)⁺.

Example 3trans-4-[3a-Fluoro-2-[(E)-3-[4-(trifluoromethoxy)phenyl]prop-2-enoyl]-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-5-carbonyl]-3-fluorobenzenesulfonamide

To a solution of3-fluoro-4-((3aR,6aS)-3a-fluorooctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzenesulfonamidehydrochloride (intermediate 9; 50 mg, 122 μmol), 4-methylmorpholine(61.9 mg, 612 μmol) and (E)-3-(4-(trifluoromethoxy)phenyl)acrylic acid(29 mg, 122 μmol) in N,N-dimethylformamide (4 mL) was addedO-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluoro-phosphate (46.5 mg, 122 μmol) at room temperature, then after18 h the reaction mixture was partitioned between sat. aq. sodiumhydrogen carbonate solution and ethyl acetate/2-methyltetrahydrofuran4:1. The organic layer was washed with sat. aq. ammonium chloridesolution and brine, dried over magnesium sulfate filtered andevaporated. Chromatography (silica gel; gradientdichloromethane/methanol/25% aq. ammonia solution 97.5:2.5:0.25 to95:5:0.25) afforded the title compound (48 mg, 72%). White solid, MS:546.1 (M+H)⁺.

The following examples were produced in analogy to example 3, replacing3-fluoro-4-((3aR,6aS)-3a-fluorooctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzenesulfonamidehydrochloride by the appropriate amine and(E)-3-(4-(trifluoromethoxy)phenyl)acrylic acid by the appropriatecarboxylic acid.

MS, Ex. Systematic name Amine/Carboxylic acid m/e 3.01

3-fluoro-4-(trans-3a- fluorooctahydro- pyrrolo[3,4-c]pyrrole-2-carbonyl)benzenesulfonamide hydrochloride (intermediate 9)/2-(4-(trifluoromethoxy)phenoxy)acetic acid (CAS-RN 72220-50-9) 548.2 (M + H)⁺3.02

3-fluoro-4-(trans-3a- fluorooctahydro- pyrrolo[3,4-c]pyrrole-2-carbonyl)benzenesulfonamide hydrochloride (intermediate 9)/2-cyclopropyl-6- ((tetrahydro-2H-pyran- 4-yl)methoxy)isonicotinic acid(intermediate 7) 591.2 (M + H)⁺ 3.03

3-fluoro-4-(trans-3a- fluorooctahydropyrrolo [3,4-c]pyrrole-2-carbonyl)benzenesulfonamide hydrochloride (intermediate 9)/3-(4-(trifluoromethoxy) phenyl)propanoic acid 546.2 (M − H)⁻

Examples 4 and 5(+)-(3aR,6aR)-3a-Methyl-5-(4-sulfamoyl-benzoyl)-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylicacid 4-trifluoromethoxy-benzyl ester and(−)-(3aS,6aS)-3a-methyl-5-(4-sulfamoylbenzoyl)-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylicacid 4-trifluoromethoxy-benzyl ester

Racemictrans-3a-methyl-5-(4-sulfamoyl-benzoyl)-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylicacid 4-trifluoromethoxy-benzyl ester (example 1.06; 180 mg, 341 μmol)was separated by preparative HPLC using Chiralpak AD as the stationaryphase and heptane/ethanol/ammonium acetate 60:40:0.004 as the eluent.This produced the faster eluting (+)-enantiomer (example 4; 67 mg, 37%;white foam, MS: 528.2 (M+H)⁺) and the slower eluting (−)-enantiomer(example 5; 63 mg, 35%; white foam, MS: 528.2 (M+H)⁺).

The following examples were produced in analogy to examples 4 and 5 bychiral HPLC separation of their racemates, using stationary phase andeluent as indicated below.

Optical Stationary phase; Ex. Systematic Name rotation sign eluent MS,m/e 4.01 trans-5-(4-sulfamoyl-benzoyl)-3a- (−) Reprosil 542.3methoxy-hexahydro-pyrrolo[3,4- Chiral-NR; (M − H)⁻ 5.01c]pyrrole-2-carboxylic acid 4- (+) heptane/ 542.3trifluoromethoxy-benzyl ester ethanol/ammonium (M − H) ⁻ (example 1.05)acetate 60:40:0.004 4.02 trans-5-(4-sulfamoyl-benzoyl)-3a- (−) Reprosil530.2 fluoro-hexahydro-pyrrolo[3,4- Chiral-NR; (M − H) ⁻ 5.02c]pyrrole-2-carboxylic acid 4- (+) heptane/ 530.2trifluoromethoxy-benzyl ester ethanol/ammonium (M − H) ⁻ (example 1.04)acetate 70:30:0.003 4.03 trans-5-(4-sulfamoyl-benzoyl)-3a- (−) Reprosil628.3 methoxy-hexahydro-pyrrolo[3,4- Chiral-NR; (M + H)⁺ 5.03c]pyrrole-2-carboxylic acid 3-(2,2- (+) heptane/ethanol 628.3dimethyl-propionylamino)-5- 60:40 (M + H)⁺trifluoromethyl-pyridin-2-ylmethyl ester (example 1.03)

INTERMEDIATES Intermediate 1 trans-tert-Butyl3a-methylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate Step 1:trans-Dimethyl 1-benzyl-3-methylpyrrolidine-3,4-dicarboxylate

A solution of N-benzyl-1-methoxy-N-((trimethylsilyl)methyl)methanamine(CAS-RN 93102-05-7; 1.74 g, 17.0 mmol) in dichloromethane (5 mL) wasadded to an ice-cooled mixture of dimethyl 2-methylfumarate (CAS-RN617-53-8; 1.00 g, 6.32 mmol) and trifluoroacetic acid (79.3 mg, 696μmol) in dichloromethane (10 mL) at 0-5° C. The resulting yellowsolution was allowed to reach room temperature over 20 h, thenpartitioned between sat. aq. hydrogencarbonate solution anddichloromethane. The organic layer was washed with brine, dried overmagnesium sulfate, filtered and evaporated. Chromatography (silica gel;gradient dichloromethane to dichloromethane/methanol/25% aq. ammoniasolution 95:5:0.25) afforded the title compound (1.61 g, 87%). Lightyellow oil, MS: 292.2 (M+H)⁺.

Step 2: trans-1-tert-Butyl 3,4-dimethyl3-methylpyrrolidine-1,3,4-tricarboxylate

A solution of trans-dimethyl1-benzyl-3-methylpyrrolidine-3,4-dicarboxylate (1.56 g, 5.35 mmol) anddi-tert-butyl dicarbonate (1.29 g, 5.89 mmol) in methanol (20 mL) wasstirred at room temperature under a hydrogen atomsphere (1 bar) in thepresence of palladium (10% on activated charcoal, 165 mg, 1.55 mmol).After 3 h insoluble material was removed by filtration throughdiatomaceous earth and the filtrate was concentrated. Chromatography(silica gel; gradient heptane to ethyl acetate/heptane 1:1) afforded thetitle compound (1.47 g, 91%). Colourless oil, MS: 202.1 (M+H—Me₃COCO)⁺.

Step 3: trans-tert-Butyl3,4-bis(hydroxymethyl)-3-methylpyrrolidine-l-carboxylate

A solution of trans-1-tert-butyl 3,4-dimethyl3-methylpyrrolidine-1,3,4-tricarboxylate (1.47 g, 4.87 mmol) intetrahydrofuran (12 mL) was cooled to 0° C. and treated with lithiumborohydride solution (2 M in tetrahydrofuran, 5.47 mL, 10.9 mmol), thenafter 30 min the ice bath was removed and the reaction mixture wasstirred at room temperature. After 18 h excess reagent was destroyed byslow addition of 1 M aq. hydrochloric acid solution at 0° C. to pH 1.The resulting clear solution was extracted with dichloromethane, theorganic layer was washed with water and brine, dried over magnesiumsulfate, filtered and evaporated. Chromatography (silica gel,heptane-ethyl acetate gradient) afforded the title compound (1.05 g,88%). Colourless viscous oil, MS: 190.1 (M+H-isobutene)⁺.

Step 4: trans-tert-Butyl3-methyl-3,4-bis(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate

Methanesulfonyl chloride (1.41 g, 12.4 mmol) was added dropwise at 0° C.to a clear colourless solution of trans-tert-butyl 3,4-b is(hydroxymethyl)-3-methylpyrrolidine-1-carboxylate (1.01 g, 4.12 mmol)and N,N-diisopropylethylamine (3.19 g, 24.7 mmol) in dichloromethane (10mL) was cooled to 0° C. After 30 min the reaction mixture waspartitioned between sat. aq. ammonium chloride solution anddichloromethane. The organic layer was washed with sat. aq. sodiumhydrogencarbonate-solution and brine, dried over magnesium sulfate,filtered and evaporated. Chromatography (silica gel, heptane-ethylacetate gradient) afforded the title compound (1.53 g, 92%). Yellowviscous oil, MS: 346.1 (M+H-isobutene)⁺.

Step 5: trans-tert-Butyl5-benzyl-3a-methylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate

To a solution of trans-tert-butyl3-methyl-3,4-bis(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate(1.52 g, 3.79 mmol) in toluene (20 mL) were added triethylamine (1.15 g,11.4 mmol) and benzylamine (811 mg, 7.57 mmol). The reaction mixture washeated at reflux, then after 20 h another portion of triethylamine (1.15g, 11.4 mmol) and benzylamine (811 mg, 7.57 mmol) was added, then afteranother 20 h at reflux the reaction mixture was washed with 1 M aq.sodium hydroxide solution and brine, dried over magnesium sulfate,filtered and evaporated. Chromatography (silica gel, heptane-ethylacetate gradient) afforded the title compound (875 mg, 73%). Lightyellow solid, MS: 317.2 (M+H)⁺.

Step 6: trans-tert-Butyl3a-methylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate

A solution of (3aR,6aR)-tert-butyl5-benzyl-3a-methylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (870mg, 2.75 mmol) in methanol (10 mL) was stirred at room temperature undera hydrogen atmosphere (1 bar) in the presence of palladium (10% onactivated charcoal, 146 mg, 1.37 mmol), then after 5 h insolublematerial was removed by filtration through diatomaceous earth. Thefiltrate was evaporated to afford the title compound (640 mg, 93%)containing ca. 10% of methanol. Colourless viscous oil, MS: 227.2(M+H)⁺.

Intermediate 2 trans-tert-butyl3a-fluorohexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate

The title compound was produced in analogy to intermediate 1, replacingdimethyl 2-methylfumarate by diethyl 2-fluorofumarate (CAS-RN4495-77-6). Colourless viscous oil, MS: 231.2 (M+H)⁺.

Intermediate 3 trans-tert-Butyl3a-methoxyhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate

The title compound was produced in analogy to intermediate 1, replacingdimethyl 2-methylfumarate by dimethyl 2-methoxyfumarate (CAS-RN2215-05-6). Colourless viscous oil, MS: 243.2 (M+H)⁺.

Intermediate 4trans-3a-Methyl-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid4-trifluoromethoxy-benzyl ester hydrochloride Step 1: trans-2-tert-Butyl5-(4-(trifluoromethoxy)benzyl)3a-methyltetrahydropyrrolo[3,4-c]pyrrole-2,5(1H,3H)-dicarboxylate

To a solution of (4-(trifluoromethoxy)phenyl)methanol (474 mg, 2.47mmol) in acetonitrile (20 mL) was added 1,1′-carbonyldiimidazole (413mg, 2.47 mmol) and the reaction mixture was heated to 50° C., then after3 h triethylamine (1.25 g, 12.3 mmol) and trans-tert-butyl3a-methylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (intermediate1; 621 mg, 2.47 mmol) were added and the reaction mixture was heated atreflux. After 15 h the reaction mixture was partitioned between ethylacetate sat. aq. sodium hydrogen carbonate solution. The organic layerwas washed with aq. sat. ammonium chloride solution and brine, driedover magnesium sulfate, filtered and evaporated. Chromatography (silicagel; gradient dichloromethane to dichloromethane/methanol/25% aq.ammonia solution 95:5:0.25) afforded the title compound (821 mg, 75%).Light yellow oil, MS: 389.2 (M+H-isobutene)⁺.

Step 2: trans-3a-methyl-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylicacid 4-trifluoromethoxy-benzyl ester hydrochloride

A solution of trans-2-tert-butyl 5-(4-(trifluoromethoxy)benzyl)3a-methyltetrahydropyrrolo[3,4-c]pyrrole-2,5(1H,3H)-dicarboxylate (812mg, 1.83 mmol) and hydrochloric acid solution (5-6 M in 2-propanol, 10.2mL, 51.2 mmol) in 2-propanol (5 mL) was stirred for 15 h at roomtemperature, then concentrated to dryness. The residue was triturated intert-butyl methyl ether and the precipitate collected by filtration toproduce the title compound (662 mg, 95%). White solid, MS: 345.1 (M+H)⁺.

Intermediate 4.01trans-3a-Fluoro-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid4-trifluoromethoxy-benzyl ester

The title compound was produced in analogy to intermediate 4, replacingtrans-tert-butyl 3a-methylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate by trans-tert-butyl3a-fluorohexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (intermediate2). White solid, MS: 349.1 (M+H)⁺.

Intermediate 5trans-3a-Methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid3-(2,2-dimethyl-propionylamino)-5-trifluoromethyl-pyridin-2-ylmethylester dihydrochloride Step 1: trans-tert-Butyl5-(chlorocarbonyl)-3a-methoxyhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate

To a solution of trans-tert-butyl3a-methoxyhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (intermediate3; 440 mg, 1.82 mmol) and pyridine (646 mg, 8.17 mmol) indichloromethane (5 mL) was added dropwise a solution of triphosgene (242mg, 817 μmol) in dichloromethane (4 mL) at 0° C. After 30 min the icebath was removed, then after 4 h the reaction mixture was partitionedbetween dichloromethane and 1 M aq. hydrochloric acid solution. Theorganic layer was washed with water and brine, dried over magnesiumsulfate, filtered, and evaporated to afford the title compound (372 mg,67%) as a light yellow foam.

Step 2: trans-2-tert-Butyl5-((3-pivalamido-5-(trifluoromethyl)pyridin-2-yl)methyl)3a-methoxytetrahydropyrrolo[3,4-c]pyrrole-2,5(1H,3H)-dicarboxylate

To a solution of trans-tert-butyl5-(chlorocarbonyl)-3a-methoxyhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate(370 mg, 1.21 mmol) in acetonitrile (25 mL) was addedN-(2-(hydroxymethyl)-5-(trifluoromethyl)pyridin-3-yl)pivalamide(intermediate 8; 335 mg, 1.21 mmol) and PS-BEMP (CAS-RN 1446424-86-7;1.5 g, 1.21 mmol). The orange suspension was heated at reflux for 21 h,then insoluble material was removed by filtration. To the filtrate wasadded PS-Trisamine (CAS-RN 1226492-10-9; 315 mg, 1.21 mmol) and thereaction mixture was stirred at room temperature for 18 h, theninsoluble material was removed by filtration and the filtrate wasevaporated. Chromatography (silica gel; gradient dichloromethane todichloromethane/methanol/25% aq. ammonia 95:5:0.25) produced the titlecompound (333 mg, 50%). White foam, MS: 545.3 (M+H)⁺.

Step 3: trans-3a-Methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylicacid3-(2,2-dimethyl-propionylamino)-5-trifluoromethyl-pyridin-2-ylmethylester dihydrochloride

A solution of trans-2-tert-butyl5-((3-pivalamido-5-(trifluoromethyl)pyridin-2-yl)methyl)3a-methoxytetrahydropyrrolo[3,4-c]pyrrole-2,5(1H,3H)-dicarboxylate (325mg, 597 μmol) and hydrochloric acid solution (5-6 M in 2-propanol, 3.34mL, 16.7 mmol) in 2-propanol (2 mL) was stirred at room temperature for18 h, then the reaction mixture was concentrated to dryness. The residuewas triturated in tert-butyl methyl ether and the precipitate collectedby filtration to afford the title copound (291 mg, 94%). White solid,MS: 445.2 (M+H)⁺.

Intermediate 6trans-(2-Cyclopropyl-6-((tetrahydro-2H-pyran-4-yl)methoxy)pyridin-4-yl)3a-methoxyhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methanonedihydrochloride Step 1: trans-tert-Butyl5-(2-cyclopropyl-6-((tetrahydro-2H-pyran-4-yl)methoxy)isonicotinoyl)-3a-methoxyhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate

To a solution of trans-tert-butyl3a-methoxyhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (500 mg, 2.06mmol) in N,N-dimethylformamide (40 mL) were added2-cyclopropyl-6-((tetrahydro-2H-pyran-4-yl)methoxy)isonicotinic acid(intermediate 7; 572 mg, 2.06 mmol) and 4-methylmorpholine (1.04 g, 10.3mmol). The solution was cooled to 0° C., thenO-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluoro-phosphate (824 mg, 2.17 mmol) was added. The ice bath wasremoved, then after 96 h the reaction mixture was partitioned betweensodium hydrogencarbonate solution and ethylacetate/2-methyltetrahydrofuran 4:1. The organic layer was washed withsat. aq. ammonium chloride solution and brine, dried over magnesiumsulfate, filtered, and evaporated. Chromatography (silica gel; gradientdichloromethane to dichloromethane/methanol/25% aq. ammonia solution90:10:0.25 afforded the title compound (977 mg; 94%). Yellow viscousoil, MS: 502.3 (M+H)⁺.

Step 2:trans-(2-Cyclopropyl-6-((tetrahydro-2H-pyran-4-yl)methoxy)pyridin-4-yl)3a-methoxyhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methanonedihydrochloride

A solution of trans-tert-butyl5-(2-cyclopropyl-6-((tetrahydro-2H-pyran-4-yl)methoxy)isonicotinoyl)-3a-methoxyhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate(977 mg, 1.95 mmol) and hydrochloric acid solution (5-6 M in 2-propanol,8.57 mL, 42.8 mmol). in 2-propanol (8 mL) was stirred at roomtemperature for 16 h, then the reaction mixture was concentrated todryness. The residue was triturated in tert-butyl methyl ether and theprecipitate collected by filtration to afford the title compound (858mg, 88%). White solid, MS: 402.3 (M+H)⁺.

Intermediate 6.01trans-1-(3a-methoxyhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-(4-(trifluoromethoxy)phenyl)propan-1-onedihydrochloride

The title compound was produced in analogy to example 6, replacing2-cyclopropyl-6-((tetrahydro-2H-pyran-4-yl)methoxy)isonicotinic acid by3-(4-(trifluoromethoxy)phenyl)propanoic acid. Brown viscous oil, MS:359.2 (M+H)⁺.

Intermediate 72-Cyclopropyl-6-((tetrahydro-2H-pyran-4-yl)methoxy)isonicotinic acidStep 1: Methyl 6-cyclopropyl-2-oxo-1,2-dihydropyridine-4-carboxylate

A suspension of 6-cyclopropyl-2-oxo-1,2-dihydropyridine-4-carboxylicacid (CAS-RN 150190-28-6; 400 mg, 2.23 mmol) in methanol (4 mL) andsulfuric acid (12 μL) was added was heated at 70° C. for 48 h, thenconcentrated in vacuo. The residue was suspended in dichloromethane (10mL), then insoluble material was removed by filtration and the filtrateevaporated to produce the title compound (427 mg, 99%). Light brownsemisolid, MS: 194.1 (M+H)⁺.

Step 2: Methyl2-cyclopropyl-6-((tetrahydro-2H-pyran-4-yl)methoxy)isonicotinate

To a stirring suspension of methyl6-cyclopropyl-2-oxo-1,2-dihydropyridine-4-carboxylate (212 mg, 1.1 mmol)in acetonitrile (5 mL) were added potassium carbonate (455 mg, 3.29mmol) and 4-(iodomethyl)tetrahydro-2H-pyran (CAS-RN 101691-94-5; 744 mg,3.29 mmol). The reaction mixture was heated at 80° C. for 16 h and thenevaporated in vacuo. The residue was purified by chromatography (silicagel; heptane-ethyl acetate gradient) to produce the title compound (188mg, 59%). Colourless oil, MS: 292.2 (M+H)⁺.

Step 3: 2-Cyclopropyl-6-((tetrahydro-2H-pyran-4-yl)methoxy)isonicotinicacid

To a solution of methyl2-cyclopropyl-6-((tetrahydro-2H-pyran-4-yl)methoxy)isonicotinate (184mg, 632 μmol) in tetrahydrofuran (2 mL) and water (2 mL) was addedlithium hydroxide monohydrate (53.0 mg, 1.26 mmol) and the resultingmixture stirred at room temperature for 16 h. The mixture was partiallyevaporated in order to remove the tetrahydrofuran. The aqueous phase waspartitioned between 1 M aq. hydrochloric acid solution and ethylacetate. The organic layer was washed with brine, dried over magnesiumsulfate, filtered and evaporated to give the title compound (218 mg,quant.). Colourless oil, MS: 276.1 (M−H)⁻.

Intermediate 8N-(2-(Hydroxymethyl)-5-(trifluoromethyl)pyridin-3-yl)pivalamide Step 1:Methyl 3-pivalamido-5-(trifluoromethyl)picolinate

To a brown solution of methyl 3-amino-5-(trifluoromethyl)picolinate(CAS-RN 866775-17-9; 2.00 g, 8.63 mmol) in pyridine (25 mL) was addedpivaloyl chloride (2.08 g, 17.3 mmol) at 0° C. After 20 min the ice-bathwas removed, then after 5 h the reaction mixture was partitioned between1 M aq. hydrochloric acid solution and ethyl acetate. The organic layerwas washed with water and brine, dried over magnesium sulfate, filteredand evaporated. Chromatography (silica gel; heptante-ethyl acetategradient) afforded the title compound (2.46 g, 92%). Light yellow solid,MS: 305.1 (M+H)⁺.

Step 2: N-(2-(Hydroxymethyl)-5-(trifluoromethyl)pyridin-3-yl)pivalamide

To a clear light yellow solution of methyl3-pivalamido-5-(trifluoromethyl)picolinate (2.45 g, 8.05 mmol) intetrahydrofuran (60 mL) was added a solution of calcium chloride (1.79g, 16.1 mmol) in ethanol (60 mL), then sodium borohydride (914 mg, 24.2mmol) was added in three portions over a period of 30 min. The whitesuspension was stirred for 90 min at room temperature, then partitionedbetween water and sat. aq. ammonium chloride solution. The organic layerwas washed with brine, dried over magnesium sulfate, filtered, andevaporated. Chromatography (silica gel; heptane-ethyl acetate gradient)afforded the title compound (1.97 g; 89%). Light yellow viscous oil, MS:277.1 (M+H)⁺.

Intermediate 93-Fluoro-4-(trans-3a-fluorooctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzenesulfonamidehydrochloride Step 1: trans-tert-butyl3a-fluoro-5-(2-fluoro-4-sulfamoylbenzoyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate

The title compound was produced in analogy to intermediate 6, step 1,replacing trans-tert-butyl3a-methoxyhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate bytrans-tert-butyl3a-fluorohexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate and2-cyclopropyl-6-((tetrahydro-2H-pyran-4-yl)methoxy)isonicotinic acid by2-fluoro-4-sulfamoylbenzoic acid (CAS-RN 714968-42-0). Light yellowfoam, MS: 432.2 (M+H)⁻.

Step 2:3-Fluoro-4-(trans-3a-fluorooctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzenesulfonamidehydrochloride

The title compound was produced in analogy to intermediate 6, step 2from trans-tert-butyl3a-fluoro-5-(2-fluoro-4-sulfamoylbenzoyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate.White solid, MS: 332.0 (M+H)⁺.

Example A

A compound of formula (I) can be used in a manner known per se as theactive ingredient for the production of tablets of the followingcomposition:

Per tablet Active ingredient 200 mg Microcrystalline cellulose 155 mgCorn starch  25 mg Talc  25 mg Hydroxypropylmethylcellulose  20 mg 425mg

Example B

A compound of formula (I) can be used in a manner known per se as theactive ingredient for the production of capsules of the followingcomposition:

Per capsule Active ingredient 100.0 mg Corn starch  20.0 mg Lactose 95.0 mg Talc  4.5 mg Magnesium stearate  0.5 mg 220.0 mg

1. Compounds of formula (I)

wherein R¹ is substituted phenyl, substituted phenyl-C₁₋₆-alkyl,substituted phenoxy-C₁₋₆-alkyl, substituted phenyl-C₂₋₆-alkenyl,substituted phenyl-C₂₋₆-alkynyl, substituted pyridinyl, substitutedpyridinyl-C₁₋₆-alkyl, substituted pyridinyl-C₂₋₆-alkenyl, substitutedpyridinyl-C₂₋₆-alkynyl, substituted thiophenyl, substitutedthiophenyl-C₁₋₆-alkyl, substituted thiophenyl-C₂₋₆-alkenyl orsubstituted thiophenyl-C₂₋₆-alkynyl, wherein substituted phenyl,substituted phenyl-C₁₋₆-alkyl, substituted phenoxy-C₁₋₆-alkyl,substituted phenyl-C₂₋₆-alkenyl, substituted phenyl-C₂₋₆-alkynyl,substituted pyridinyl, substituted pyridinyl-C₁₋₆-alkyl, substitutedpyridinyl-C₂₋₆-alkenyl, substituted pyridinyl-C₂₋₆-alkynyl, substitutedthiophenyl, substituted thiophenyl-C₁₋₆-alkyl, substitutedthiophenyl-C₂₋₆-alkenyl and substituted thiophenyl-C₂₋₆-alkynyl aresubstituted by R³, R⁴ and R⁵; Y is —OC(O)— or —C(O)—; W is —C(O)—,—S(O)₂— or —CR⁶R⁷—; R² is substituted phenyl, substituted pyridinyl orsubstituted thiophenyl, wherein substituted phenyl, substitutedpyridinyl and substituted thiophenyl are substituted by R⁶, R⁷ and R⁸;R³ is halogen, hydroxy, cyano, C₁₋₆-alkyl, C₁₋₆-alkoxy,C₁₋₆-alkoxy-C₁₋₆-alkyl, halo-C₁₋₆-alkoxy, halo-C₁₋₆-alkyl,hydroxy-C₁₋₆-alkyl, C ₃₋₈-cycloalkyl, C ₃₋₈-cycloalkyl-C₁₋₆-alkyl,C₃₋₈-cycloalkyl-C₁₋₆-alkoxy, C ₃₋₈-cycloalkoxy, C₃₋₈-cycloalkoxy-C₁₋₆-alkyl, C₁₋₆-alkylamino, C₁₋₆-alkylcarbonylamino,C₃₋₈-cycloalkylcarbonylamino, C₁₋₆-alkyltetrazolyl,C₁₋₆-alkyltetrazolyl-C₁₋₆-alkyl or heterocycloalkyl-C₁₋₆-alkoxy; R⁴ andR⁵ are independently selected from H, halogen, hydroxy, cyano,C₁₋₆-alkoxy, C₁₋₆-alkoxy-C₁₋₆-alkyl, halo-C₁₋₆-alkoxy,hydroxy-C₁₋₆-alkyl, C₃₋₈-cycloalkyl, C₃₋₈-cycloalkyl-C₁₋₆-alkoxy,C₃₋₈-cycloalkoxy, C₃₋₈-cycloalkoxy-C₁₋₆-alkyl, C₁₋₆-alkylcarbonylamino,C₃₋₈-cycloalkylcarbonylamino, C₁₋₆-alkyltetrazolyl,C₁₋₆-alkyltetrazolyl-C₁₋₆-alkyl or heterocycloalkyl-C₁₋₆-alkoxy; R⁶ isaminosulfonyl; R⁷ and R⁸ are independently selected from H, halogen,hydroxy, cyano, C₁₋₆-alkoxy, C₁₋₆-alkoxy-C₁₋₆-alkyl, halo-C₁₋₆-alkoxy,hydroxy-C₁₋₆-alkyl, C₃₋₈-cycloalkyl, C₃₋₈-cycloalkyl-C₁₋₆-alkoxy,C₃₋₈-cycloalkoxy and C₃₋₈-cycloalkoxy-C₁₋₆-alkyl; R⁹ is C₁₋₆-alkyl,C₁₋₆-alkoxy or halogen; m, n, p and q are independently selected from 1or 2; or pharmaceutically acceptable salts.
 2. A compound according toclaim 1, wherein R¹ is substituted phenyl-C₁₋₆-alkyl, substitutedphenoxy-C₁₋₆-alkyl, substituted phenyl-C₂₋₆-alkenyl, substitutedpyridinyl or substituted pyridinyl-C₁₋₆-alkyl, wherein substitutedphenyl-C₁₋₆-alkyl, substituted phenoxy-C₁₋₆-alkyl, substitutedphenyl-C₂₋₆-alkenyl, substituted pyridinyl and substitutedpyridinyl-C₁₋₆-alkyl are substituted by R³, R⁴ and R⁵; Y is a —OC(O)— or—C(O)—; W is —C(O)—; R² is substituted phenyl or substituted pyridinyl,wherein substituted phenyl and substituted pyridinyl are substituted byR⁶, R⁷ and R⁸; R³ is halo-C₁₋₆-alkoxy, C₁₋₆-alkylcarbonylamino ortetrahydropyranyl-C₁₋₆-alkoxy; R⁴ is H, C₁₋₆-alkyl or C₃₋₈-cycloalkyl;R⁵ is H; R⁶ is aminosulfonyl; R⁷ and R⁸ are independently selected fromH and halogen; R⁹ is C₁₋₆-alkyl, C₁₋₆-alkoxy or halogen; m,n, p and qare 1; or pharmaceutically acceptable salts.
 3. A compound according toclaim 1 or 2, wherein R¹ is substituted phenyl-C₁₋₆-alkyl, substitutedphenoxy-C₁₋₆-alkyl, substituted phenyl-C₂₋₆-alkenyl, substitutedpyridinyl or substituted pyridinyl-C₁₋₆-alkyl, wherein substitutedphenyl-C₁₋₆-alkyl, substituted phenoxy-C₁₋₆-alkyl, substitutedphenyl-C₂₋₆-alkenyl, substituted pyridinyl and substitutedpyridinyl-C₁₋₆-alkyl are substituted by R³, R⁴ and R⁵.
 4. A compoundaccording to any one of claims 1 to 3, wherein R¹ is substitutedpyridinyl or substituted pyridinyl-C₁₋₆-alkyl, wherein substitutedpyridinyl and substituted pyridinyl-C₁₋₆-alkyl are substituted by R³, R⁴and R⁵.
 5. A compound according to any one of claims 1 to 4, wherein Yis —C(O)—.
 6. A compound according to any one of claims 1 to 2, whereinR² is substituted phenyl or substituted pyridinyl, wherein substitutedphenyl and substituted pyridinyl are substituted by R⁶, R⁷ and R⁸.
 7. Acompound according to any one of claims 1 to 7, wherein R³ ishalo-C₁₋₆-alkoxy, C₁₋₆-alkylcarbonylamino ortetrahydropyranyl-C₁₋₆-alkoxy.
 8. A compound according to any one ofclaims 1 to 8, wherein R³ is tetrahydropyranyl-C₁₋₆-alkoxy.
 9. Acompound according to any one of claims 1 to 9, wherein R⁴ is H,C₁₋₆-alkyl or C₃₋₈-cycloalkyl.
 10. A compound according to any one ofclaims 1 to 10, wherein R⁴ is C₃₋₈-cycloalkyl.
 11. A compound accordingto any one of claims 1 to 11, wherein R⁵ is H.
 12. A compound accordingto any one of claims 1 to 12, wherein R⁷ and R⁸ are independentlyselected from H and halogen.
 13. A compound according to any one ofclaims 1 to 13, wherein R⁷ is H or halogen.
 14. A compound according toany one of claims 1 to 14, wherein R⁸ is H.
 15. A compound according toany one of claims 1 to 14, wherein R⁹ is halogen or C₁₋₆-alkoxy.
 16. Acompound according to any one of claims 1 to 16, wherein m, n, p and qare
 1. 17. A compound according to any one of claims 1 to 17, wherein R¹is substituted pyridinyl or substituted pyridinyl-C₁₋₆-alkyl, whereinsubstituted pyridinyl and substituted pyridinyl-C₁₋₆-alkyl aresubstituted by R³, R⁴ and R⁵; Y is —C(O)—; W is —C(O)—; R² issubstituted phenyl or substituted pyridinyl, wherein substituted phenyland substituted pyridinyl are substituted by R⁶, R⁷ and R⁸; R³ istetrahydropyranyl-C₁₋₆-alkoxy; R⁴ is C₃₋₈-cycloalkyl; R⁵ is H; R⁶ isaminosulfonyl; R⁷ is H or halogen; R⁸ is H; R⁹ is halogen orC₁₋₆-alkoxy; m, n, p and q are 1 or pharmaceutically acceptable salts.18. A compound according to claim 1 and of formula 1(a),

wherein R¹ is substituted phenyl-C₁₋₆-alkyl, substitutedphenoxy-C₁₋₆-alkyl, substituted phenyl-C₂₋₆-alkenyl, substitutedpyridinyl or substituted pyridinyl-C₁₋₆-alkyl, wherein substitutedphenyl-C₁₋₆-alkyl, substituted phenoxy-C₁₋₆-alkyl, substitutedphenyl-C₂₋₆-alkenyl, substituted pyridinyl and substitutedpyridinyl-C₁₋₆-alkyl are substituted by R³, R⁴ and R⁵; Y is a —OC(O)— or—C(O)—; W is —C(O)—; R² is substituted phenyl or substituted pyridinyl,wherein substituted phenyl and substituted pyridinyl are substituted byR⁶, R⁷ and R⁸; R³ is halo-C₁₋₆-alkoxy, C₁₋₆-alkylcarbonylamino ortetrahydropyranyl-C₁₋₆-alkoxy; R⁴ is H, C₁₋₆-alkyl or C ₃₋₈-cycloalkyl;R⁵ is H; R⁷ and R⁸ are independently selected from H and halogen; R⁹ isC₁₋₆-alkyl, C₁₋₆-alkoxy or halogen; m,n, p and q are 1; orpharmaceutically acceptable salts.
 19. A compound according to claim 1and of formula I(b),

wherein R¹ is substituted pyridinyl or substituted pyridinyl-C₁₋₆-alkyl,wherein substituted pyridinyl and substituted pyridinyl-C₁₋₆-alkyl aresubstituted by R³, R⁴ and R⁵; Y is —C(O)—; W is —C(O)—; R² issubstituted phenyl or substituted pyridinyl, wherein substituted phenyland substituted pyridinyl are substituted by R⁶, R⁷ and R⁸; R³ istetrahydropyranyl-C₁₋₆-alkoxy; R⁴ is C₃₋₈-cycloalkyl; R⁵ is H; R⁷ is Hor halogen; R⁸ is H; R⁹ is halogen or C₁₋₆-alkoxy; m, n, p and q are 1or pharmaceutically acceptable salts.
 20. A compound according to anyone of claims 1 to 20, selected fromtrans-5-(2-fluoro-4-sulfamoyl-benzoyl)-3a-methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid3-(2,2-dimethyl-propionylamino)-5-trifluoromethyl-pyridin-2-ylmethylester;trans-4-[3a-methoxy-2-[3-[4-(trifluoromethoxy)phenyl]propanoyl]-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-5-carbonyl]-3-fluorobenzenesulfonamide;trans-4-[5-[2-cyclopropyl-6-(oxan-4-ylmethoxy)pyridine-4-carbonyl]-3a-methoxy-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-2-carbonyl]-3-fluorobenzenesulfonamide;trans-5-(4-sulfamoyl-benzoyl)-3a-methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylicacid3-(2,2-dimethyl-propionylamino)-5-trifluoromethyl-pyridin-2-ylmethylester;trans-5-(4-sulfamoyl-benzoyl)-3a-fluoro-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylicacid 4-trifluoromethoxy-benzyl ester;trans-5-(4-sulfamoyl-benzoyl)-3a-methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylicacid 4-trifluoromethoxy-benzyl ester;trans-3a-methyl-5-(4-sulfamoyl-benzoyl)-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylicacid 4-trifluoromethoxy-benzyl ester;trans-5-(5-sulfamoylpyridine-2-carbonyl)-3a-methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylicacid3-(2,2-dimethyl-propionylamino)-5-trifluoromethyl-pyridin-2-ylmethylester;trans-6-[3a-methoxy-2-[3-[4-(trifluoromethoxy)phenyl]propanoyl]-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-5-carbonyl]pyridine-3-sulfonamide;trans-6-[5-[2-cyclopropyl-6-(oxan-4-ylmethoxy)pyridine-4-carbonyl]-3a-methoxy-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-2-carbonyl]pyridine-3-sulfonamide;trans-5-(2-fluoro-4-sulfamoyl-benzoyl)-3a-fluoro-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylicacid 4-trifluoromethoxy-benzyl ester;trans-4-[3a-fluoro-2-[(E)-3-[4-(trifluoromethoxy)phenyl]prop-2-enoyl]-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-5-carbonyl]-3-fluorobenzenesulfonamide;trans-4-[3a-fluoro-242-[4-(trifluoromethoxy)phenoxy]acetyl]-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-5-carbonyl]-3-fluorobenzenesulfonamide;trans-4-[5-[2-cyclopropyl-6-(oxan-4-ylmethoxy)pyridine-4-carbonyl]-3a-fluoro-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-2-carbonyl]-3-fluorobenzenesulfonamide;trans-4-[3a-fluoro-2-[3-[4-(trifluoromethoxy)phenyl]propanoyl]-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-5-carbonyl]-3-fluorobenzenesulfonamide;(+)-(3aR, 6aR)-3a-methyl -5-(4-sulfamoyl-benzoyl)-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid 4-trifluoromethoxy-benzyl ester;(−)-trans-5-(4-sulfamoyl-benzoyl)-3a-methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylicacid 4-trifluoromethoxy-benzyl ester;(−)-trans-5-(4-sulfamoyl-benzoyl)-3a-fluoro-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylicacid 4-trifluoromethoxy-benzyl ester;(−)-trans-5-(4-sulfamoyl-benzoyl)-3a-methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid3-(2,2-dimethyl-propionylamino)-5-trifluoromethyl-pyridin-2-ylmethylester;(−)-(3aS,6aS)-3a-methyl-5-(4-sulfamoylbenzoyl)-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylicacid 4-trifluoromethoxy-benzyl ester;(+)-trans-5-(4-sulfamoyl-benzoyl)-3a-methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylicacid 4-trifluoromethoxy-benzyl ester;(+)-trans-5-(4-sulfamoyl-benzoyl)-3a-fluoro-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylicacid 4-trifluoromethoxy-benzyl ester;(+)-trans-5-(4-sulfamoyl-benzoyl)-3a-methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylicacid3-(2,2-dimethyl-propionylamino)-5-trifluoromethyl-pyridin-2-ylmethylester; and pharmaceutically acceptable salts thereof.
 21. A compoundaccording to any one of claims 1 to 21, selected fromtrans-4-[5-[2-cyclopropyl-6-(oxan-4-ylmethoxy)pyridine-4-carbonyl]-3a-methoxy-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-2-carbonyl]-3-fluorobenzenesulfonamide;trans-6-[5-[2-cyclopropyl-6-(oxan-4-ylmethoxy)pyridine-4-carbonyl]-3a-methoxy-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-2-carbonyl]pyridine-3-sulfonamide;trans-4-[5-[2-cyclopropyl-6-(oxan-4-ylmethoxy)pyridine-4-carbonyl]-3a-fluoro-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-2-carbonyl]-3-fluorobenzenesulfonamide;and pharmaceutically acceptable salts thereof.
 22. A process to preparea compound according to any one of claims 1 to 22 comprising thereaction of a compound of formula (II) in the presence of a compound offormula (III), wherein R¹, R², R⁹, m, n, p and q are as defined in anyone of claims 1 to 22 and W is —C(O)—.


23. A compound according to any one of claims 1 to 22 for use astherapeutically active substance.
 24. A pharmaceutical compositioncomprising a compound according to any one of claims 1 to 22 and atherapeutically inert carrier.
 25. The use of a compound according toany one of claims 1 to 22 for the treatment or prophylaxis of ocularconditions.
 26. A compound according to any one of claims 1 to 22 forthe treatment or prophylaxis of ocular conditions.
 27. The use of acompound according to any one of claims 1 to 22 for the preparation of amedicament for the treatment or prophylaxis of ocular conditions.
 28. Amethod for the treatment or prophylaxis ocular conditions, which methodcomprises administering an effective amount of a compound according toany one of claims 1 to
 22. 29. A compound according to any one of claims1 to 22, when manufactured according to a process of claim
 26. 30. Theinvention as hereinbefore described.